Index

Note: Page entries in italics indicate figures; tables are noted with t.

AA. See Adventitious agents
ABBP. See American Association of Bovine Practitioners
AAEP. See American Association of Equine Practitioners
AAFP. See American Academy of Family Physicians; American Association of Feline Practitioners
AAHA. See American Animal Hospital Association
AASRP. See American Association of Small Ruminant Practitioners
AAV. See Adeno-associated viruses
Abscesses, 63
Accelerated approval regulation, 222–223
Accelerated development and implementation plan, 328
Access, equitable, 340
Acellular bacterium vaccine, doses and routes of administration for, 159t
Acellular pertussis vaccine, 7, 8, 166–167, 250
Acid degradable polyketals, 146
ACIP. See Advisory Committee on Immunization Practices
ACT. See Adenylate cyclase toxin
Actinobacillus pleuropneumoniae, 143
Action stage of behavior change, applied to vaccine decision making, 342, 342t
Active immunization, 154t
defined, 153
licensed vaccines for humans and, 155–156
Active immunotherapy, 179
Active surveillance, 291–292
defined, 291
effectiveness of, 292
through studies, 293
Active vaccination, defined, 114
Acute flaccid paralysis, 52, 53
Acute respiratory illness, defined, 310
Adacel, 281
Adaptive host defenses, evasion of, 67
Adaptive immune response, 59, 65, 71
antigen-specific, 73, 74
development of, 78–79
differentiation of, 76
in gut mucosa, development and retention of, 87
Adaptive immune system, 73
“self” from “non-self” distinguished by, 93
Adaptive immunity, bridging innate immunity and, 77–78
Adeno-associated viruses, 132–133
Adenovirus DNA delivery, manufacturing process and vaccine examples, 248t
Adenoviruses, 132
structure of, 133
vectors, 129
Adenylate cyclase toxin, 166
Adhesins, 66
ADIP. See Accelerated development and implementation plan
Adjuvants, 93–108, 144–145
aluminum salt-based, 98–99
antigen delivery vehicles, 97–98
bacterial toxins, 105–106
chemokine, potential roles of, 116t
combination, 106
CpG oligonucleotides, 104
defined, 93, 165
eмуlсiоns, 99–100
future challenges with, 107–108
gone wrong, 117
good, characteristics of, 95
immunology of protection and, 116
immunostimulatory, 102, 104
in inactivated vaccines, 165
innate immune system and, 149
licensed and developmental, examples of, 94t
liposomes, 100–101
for materials-based vaccines, 150
microparticles/nanoparticles, 101–102
monophosphoryl lipid A, 104–105
muramyl dipeptide, 105
novel, 117
safety of, 96–97
saponins, 102
TLR3/RIG-I ligands, 105
TRL5 agonists: flagellin, 105
types of, 97–106
unknown mechanism of action for, 145
for veterinary vaccines, 106–107
Adventitious agents, 255 defined, 200, 249 t
Adventitious viruses, quality control testing and, 201 t
Adverse events communication about, 301 defined, 288, 331 intussusception following receipt of rotavirus vaccine, 289, 292
Adverse events following immunization, 292, 296 causality of, 297, 298 vaccine pharmacovigilance and, 288
Advisory Committee on Immunization Practices, 43, 274, 275, 276, 281, 294, 310, 340, 353
Aedes aegypti mosquitoes, 9, 71 AEFI. See Adverse events following immunization
Alphaviruses structure of, 135 vectors, 133–135 ALT. See Alanine transaminase
Antigen delivery
novel systems for, 139
strategies for, 146–149
vehicles for, 97–98, 99
Antigen encapsulation and
presentation, strategies for, 145–146
Antigen-loaded ISCOMs, local events
following injection of, 101
Antigen presentation, by dendritic
cells, 147
Antigen-presenting cells, 98, 100,
143, 179
Antigen-specific adaptive immune
response, 74
Antigen-specific memory B cells, 81
Antigen-specific T cells, 81
Antigens
mucosal immunization with,
challenges related to, 88
self-derived, vaccination
against, 115
t cell-independent, 84
in vaccine manufacture, 244, 247
harvesting of, 247
purification of, 247
Antiparasitic drugs, in veterinary
medicine, 187
Antitoxins, 2
Apathogenic virus, 112, 112
APCs. See Antigen-presenting cells
APEC. See Asia-Pacific Economic
Cooperation
APHIS. See Animal and Plant Health
Inspection Service
Apoptosis-associated speck-like
protein, 76, 77
Approval of vaccines
accelerated, 222–223
fast track, 222
priority review, 223
APRIL, 81, 92
Aquaculture
defined, 188
vaccine status for, 188–190
Aracaju, rotavirus diarrhea in
children in, 31
Archeosomes, 100–101
ARI. See Acute respiratory illness
ARTG. See Australian Register of
Therapeutic Goods
Arthritis, 114
ASC. See Apoptosis-associated
speck-like protein
ASEAN. See Association of Southeast
Asian Nations
Aseptic meningitis, measles, mumps
vaccine-associated, 302
AS15, 106
Asia-Pacific Economic
Cooperation, 268
ASO2, 106
ASO3, 106
ASO4, 106
Aspartate aminotransferase, 113
Asplenia, vaccine recommendations
for, 283
Assays
in quality control of vaccines,
253
in vaccine manufacturing, 250
Association of Southeast Asian
Nations, 268
AST. See Aspartate aminotransferase
ATAGI. See Australian Technical
Advisory Group on Immunisation
ATCC. See American Type Culture
Collection
Attenuation, 2
Attributional framework, applied to
vaccine decision making, 346
Atypical measles, 14
Audits, 267, 268, 332
Australia
clinical trials in, 265–266
vaccine licensure in, 36
vaccination vaccine regulations
in, 238
Australian Pesticides and Veterinary
Medicines Authority, 333
Australian Register of Therapeutic
Goods, 228
Australian Technical Advisory Group
on Immunisation, 275
Autism, fears about MMR vaccine
and, 298–299, 343, 345–346
Autographa californica nuclear
polyhedrosis virus, recombinant
influenza vaccine and, 171
Autologous cellular
immunotherapy, 179
Autonomy, parental, 350, 351
Autotransporter proteins, 141
AVA. See Anthrax vaccine adsorbed
Availability heuristic, applied to
vaccine decision making, 345,
346
Avian influenza virus, 132
chimeric vaccines for, 185
“marker vaccines” and, 114
Avipox vectors, 132
Avipoxvirus, 130
AVMA. See American Veterinary
Medical Association
Avoidance of ambiguity, applied to
vaccine decision making, 347
B-cell activating factor, defined, 81
B-cell memory cells, persistent
production of, 82–83
B-cell receptor (BCR) complex, 80
B-cell receptors, defined, 81
B cells, adaptive immune responses in
gut mucosa and, 87
B lymphocytes, 73, 78
antigen delivery vehicles and, 97
immunity and, 80
Bacille Calmette-Guérin infection,
IMPACT identification of, 292
Bacillus anthracis, 69, 176, 177
S-layer proteins EA1 and Sap
ol, 142
Bacillus anthracis lethal toxin, 67
Bacillus Calmette-Guérin (BCG)
vaccine, 142, 156, 325
Bacillus subtilis, lipoprotein DppE
of, 141
Bacteria, veterinary vaccines
against, 186–187
Bacterial cell surface display
systems, 139, 140
Bacterial diseases
global vaccine preventable, 320
for vaccine research and
development, 321
Bacterial endotoxin assay, 250
Bacterial ghost (BG) systems, 139,
142–143, 150
Bacterial ghosts, 143
Bacterial pathogens, portals of entry
for, 62
Bacterial pneumonia, 28
Bacterial polysaccharide (Streptococcus pneumoniae), development and production of, 203–205
Bacterial subunit vaccines, 166
Bacterial toxin mediated damage, mechanisms of, 69
Bacterial toxins, 105–106
Bacterial vaccines, recently commercialized, by target animal, 186
t
Bacterial vectors, as vaccine platforms, 139–142
bacterial cell surface display systems, 140
gram-negative display systems, 140–141
gram-positive display systems, 141–142
Baculovirus master and working seeds, recombinant HPV VLP vaccines and control of, 255
BAFF. See B-cell activating factor
Bandwagoning, 343
applied to vaccine decision making, 346
Basic reproductive number (R₀), 45
calculating, 310
defined, 308, 310–312
formula for, 311
herd immunity and, 312–313
herd immunity threshold and, 313
schematic of, 311
sexually transmitted hepatitis B virus infection and influences on, 312
values of, for well-known infectious diseases, 312
Basic science, 113, 124, 125
additional roles for, in vaccine development, 123
meaning of, 109
Bats, rabies control in, 241
BEI. See Binary ethylene-imine
Belief-dependent realism, 345, 346
Belief perseverance, 345, 346
applied to vaccine decision making, 346
“Bench to bedside,” 110
Benzethonium, 258
Benzonase, 205
Beta-propiolactone, 156
Biases, applied to vaccine decision making, 345, 346–347
Bill and Melinda Gates Foundation, 53, 323, 327, 328–329, 340
Binary ethylene-imine, 156
Biochemistry, 193
Biodefense and bioterrorism agents, vaccines for, 35, 176–177
Biofilms, 189
Bioinformatic tools, 119
Bioinformatics systems, 42, 120–123, 193
commonly used, 120
growth in, 120
Biological environmental factors, 305
Biological IND, 216–217
Biologics, regulation of, 40–42, 198, 213, 229, 291
alternative pathways to licensure, 41–42
defined, 214
meetings with regulatory agencies, 40–41
post-licensure activities, 41
Biologics Marketing Application, 291
Biomarkers, defined, 113
Biomaterials, 144–145, 148, 150
antigens encapsulated in or conjugated to, 148
defined, 145
future directions for, 149–150
natural and synthetic, 145
naturally derived, 146
polymeric, 149
strength of, as vaccine delivery platforms, 148
Biomedical researchers, vaccine recommendations for, 285
Biosafety tests, 201
Biotechnology Working Group, 256
Bioterrorism, vaccines against, 339
Bioterrorism agents, vaccine correlate of protection and, 90
Bites, disease transmission through the skin and, 60
BivWC, 166
BLA. See Biologics License Application
BLIMP-1, 81, 82
Blinded studies/blinding, 261, 262, 264
Block copolymers, 150
Bluetongue virus, 132
Bodian, David, 10
B1 B cells, 80, 81
Boosters, 156–157
for infants and children, 277
Bordetella bronchiseptica, 143
Bordetella pertussis, 2, 7, 62, 88, 90, 156, 166
Borreli burgdorferi, 171, 172
Botulism, CBRN medical countermeasures against, 285
Bovine parainfluenza virus 3, 136
Bovine viral diarrhea, alphavirus vectors tested in vaccines against, 135
Boyllston, Zabdiel, 1
BPL. See Beta-propiolactone
Brain abscesses, 63
Breast cancer, tumor vaccines against, 135
Brighton Collaboration Group, 292, 331–332
Bronfenbrenner’s ecological systems theory, 341, 343, 349
Brucella abortus, alphavirus vectors tested in vaccines against, 135
Brucella melitensis, 143
Brucella spp., 3, 177
Brucellosis, 3
Brucellosis vaccine, 177
B7-1, defined, 77
B7-2, defined, 77
B2 B cells, 80, 81
Bubonic plague, 177
Bulbar polio, 52
BWG. See Biotechnology Working Group
C-type lectin receptors, 73, 77
CAEFISS. See Canadian Adverse Event Following Immunization Surveillance System
CAEV. See Caprine arthritis encephalitis virus
Cairina retina cell line, 249
CAM-70 measles strain, 251
Campylobacter, 186

361
Canadian Adverse Event Following Immunization Surveillance System, 292
Canadian Food Inspection Agency, 333
Canadian Vaccine Safety Blueprint, 298
Canarypox recombinant vaccines and, 113 vectors, 131
Cancer fears about vaccines and, 299 vaccination against-self-derived antigens and, 114–115
Cancer vaccines personalized, 179 veterinary, 183
Canine distemper virus, 132 Capillary electrophoresis, 250 Caprine arthritis encephalitis virus, 137 Capsids, 173 Capsular polysaccharide, Streptococcus pneumoniae, 203 Carrier outer membrane proteins, for displaying passenger amino acid sequence of foreign antigen, 140
Carroll, James, 8
Case control studies, defined, 293
Catch-up vaccination schedules, 276
Cats inactivated dermatophyte vaccines for, 188 second- and third-generation licensed/commercialized viral vaccines for, 185 viruses of global importance in, 184
Cattle bacterial vaccines for, 186t inactivated dermatophyte vaccines for, 188 protozoal vaccines for, 187t second- and third-generation licensed/commercialized viral vaccines for, 185t viruses of global importance in, 184t
Causality assessment, for drugs, 296–298
CBER. See Center for Biologics Evaluation and Research
CBRN medical countermeasures, for U.S. military personnel, 285 CBT. See Cognitive behavioral therapy CCL. See Cold chain and logistics CCLs. See Continuous cell lines CCR7, 77, 78, 81
CCVD. See Channel catfish virus disease
CD80, 77
CD86, 77
CD209, 76
CD4+ T-lymphocyte counts, HIV, vaccine recommendations and, 282, 283–284
CD8+ T lymphocytes, 79
CDER. See Center for Drug Evaluation and Review
CD54+, 179
cDNA microarrays, 118
CDRH. See Center for Devices and Radiological Health
CEFs. See Chicken embryo fibroblasts
Cell bank system, defined, 249
Cell biology, 110
Cell culture

geneic reassortment and, 163
propagation of vaccine antigens in, 200
vaccine preparation and, 157
Cell lines, defined, 249t
Cell-mediated immunity, 19
Cells, infectious agents and manipulation of, 62
Cellular immune mechanisms, microbes and targeting of, 67
Cellular immunity, 2, 65
Center for Biologics Evaluation and Research, 11, 35, 38, 205, 213, 214, 216, 229, 250, 265, 266, 323, 333, 338
biological products regulated by, 220
Biologics License Application and, 40
HBV vaccine lot-to-lot release allowed by, 252
organization structure, 220
review process for INDs, 220–221
Center for Devices and Radiological Health, 220
Center for Drug Evaluation and Review, 213, 214
Center for Medicaid, 275
Center for Product Evaluation, 265, 266
Center for Veterinary Biologics, 187, 234, 333
Centers for Biologics Evaluation and Research, 5, 11, 213, 214, 220, 221, 250, 265, 266, 323, 333, 338
Centers for Disease Control and Prevention, 26, 48, 178, 199, 205, 250, 274, 291, 336, 341
Advisory Committee on Immunization Practices, 43, 274, 275, 276, 281, 294, 310, 340, 353
on food-borne pathogens, 186
H1N1 influenza pandemic of 2009 and, 310
Immunization Safety Office, 293, 295
travelers' vaccines website, 325
Vaccine Safety Datalink, 41
Central route to persuasion, in context of vaccines, 345
Centre for Immunization and Respiratory Infectious Disease, 298
Cervarix, 233
Cervical cancer, human papillomaviruses and, 26
Cervical carcinoma vaccine, 178
CFDA. See China Food and Drug Administration
CFR. See Code of Federal Regulations
cGMP. See Good manufacturing practice
Channel catfish virus disease, 190
CHAT polio virus type 1, 299
Chemistry, 110
Chemistry, manufacturing, and controls (CMC) section, IND, 218–219
control, 219
defined, 219
drug product, 218
drug substance, 218
environmental analysis requirements, 219
labeling, 219
Chemokine adjuvants, potential roles of, 116t
Chicken cholera, 244
Chicken embryo fibroblasts, 157, 205, 248, 251
Chickenpox (varicella), 2, 16, 18, 153, 309
as eradicable disease with vaccination, 178t, 323
protective immunity and, 305
SIR model and, 316
value of herd immunity threshold for, 313t
Childhood immunizations, parental refusal of, 350
Childhood vaccination
impact of, in USA, 20th century, 178t
total savings from direct/indirect costs and, 4
vaccine-preventable illnesses in U.S.and, 3t
Childhood vaccines, reformulation of, for adults/senior citizens, 178, 179
Children
asplenia in, 283
parental participation in immunization process for, 302 uninsured, 340
vaccine recommendations for, 277, 281, 286
vaccines and life expectancy of, 3
VSD study on trivalent inactivated influenza vaccine in, 294
ChimeraVax-based vaccines, construction of, 173
Chimeric vaccines, in veterinary medicine, 185
Chimeric virus vaccine candidates, 137
ChimeriVax, 137
ChimeriVax-Japanese encephalitis, 172–173
China Food and Drug Administration, 228, 256, 332
Chitin, 146
Chitosan, 146, 147, 149
Chitosan microparticles, 189
Chlamydia, 67, 199
CHMP. See Committee for Medicinal Products for Human Use
Cholera, 2, 88, 166, 320
Cholera toxin, 105
Cholera vaccine, inactivated, 166
Cholesteryl-group-bearing pullulan (cCHP), 148
Chromatography, 250
Chronic diseases, disability and, 178
Chronosystem level, vaccine decision making and, 344t
Ciprofloxacin, 301
CIRID. See Centre for Immunization and Respiratory Infectious Disease
CISA. See Clinical Immunization Safety Assessment
CL. See Cell lines
Class I MHC molecules, 79
Class II MHC molecules, 79
Classical swine fever, 185
alphavirus vectors tested in vaccines against, 135
Cleveland, “Baby” Ruth, death from diphtheria, 4, 5
Cleveland, President and Mrs. Grover, 4
Climate change, infectious diseases and, 239
Clinical evaluation of vaccines, 260–272
good clinical practice, 268
government jurisdiction, 265–266
independent ethics committees, 270–271
institutional review boards, 270–271
investigational new drug process, 266–267
investigators, 269–270
responsibilities of, 270
phases of clinical trials, 261–264
phase I, 262–263, 263t, 264, 272, 289
phase II, 261, 263, 263t, 264, 272, 289
phase III, 261, 263–264, 263t, 272, 289, 291
phase IV, 261, 263t, 264, 272, 293, 309
pivotal, 264
tropical diseases and, 332
vaccine development pathway and, 198
vaccine development process and importance of, 261
Clinical trials notification, 265
Clinical vaccinology, 193
ClinicalTrials.gov identifier number, 267
Cloning, 113
Clostridium diphtheriae, 98
Clostridium tetani, 2, 62, 68, 69, 98, 110, 111, 167, 244, 324
CMI. See Cell-mediated immunity
Co-correlate of protection, defined, 89
Coadministration, of vaccines, 174, 175, 175t
COBTA. See Council on Biologic and Therapeutic Agents
Cocooning (Cocoon Strategy), 156, 282
Code of Federal Regulations for the Protection of Human Subjects, Title 9 of, 234
Title 21 of, 207, 256
Cognitive behavioral therapy, 341, 343
Cognitive biases, vaccine decision making and, 344–347
COGs. See Cost of goods
Cohort studies, defined, 293
Cold adapted (ca), 163
Cold chain, defined, 44
logistics and, 248
between manufacturer and end user, 257
College students, vaccine recommendations for, 285
Collier, Leslie, 47
Colonization, defined, 60, 71
Combination adjuvants, 106
Combination confusion, defined, 281
Combination vaccines, 174, 175t, 281, 297
defined, 175
elements of, 324t
Commission bias, applied to vaccine decision making, 347t
Committee for Medicinal Products for Human Use, 256
Committee for Veterinary Medicinal Products, 237
Common Technical Document, modules in format, 225, 226
Communicable Disease Center, Epidemic Intelligence Service of, 215
Communicable diseases, transmission of, 59
Communicable Diseases Center, 338. See also Centers for Disease Control and Prevention
Communicable infections, 60
Communication, vaccine safety and, 300
Communication pathways, creating, 302, 303
Companion animals defined, 183, 233
potential emerging zoonotic diseases in, 242
vaccine selection for, 181–183
Comparative pathogenesis, 111
by expression profiling, 112
mechanisms of disease and, 110–111
Complement proteins, 65
Complementary DNA (cDNA), 172
Computational biology, 110
Computational tools, 119
Concomitant vaccines, defined, 175
Conditional licenses, 234
Confidence
parental, 302
in vaccine safety, 298
Confirmation bias, applied to vaccine decision making, 346, 347
Conflicts of interest, institutional review board members and, 271
Congenital rubella syndrome, 15, 15, 336
Conjugate bacterium vaccine, doses and routes of administration for, 160t
Conjugate vaccines, 161t, 168–169, 179
defined, 153
examples of, 154t
Contemplation stage of behavior change, applied to vaccine decision making, 342, 342t
Continuous cell lines, 248–249
Contract research organizations, 208, 267, 269
Control, defined, 45
Control groups, defined, 262
Controlled, randomized, and double blinded clinical trials, 264
Core vaccines, for companion and food-producing animals, 182
Coronaviruses, 139
Correlate of protective immunity, defined, 237
Correlates of protection defined, 89, 203
vaccine efficacy, future vaccine improvement and, 88–89
Corynebacterium diphtheriae, 2, 4, 62, 68, 69, 167
Corynebacterium diphtheriae CRM197 protein, 168, 169
Cost of goods, 250
Council on Biologic and Therapeutic Agents, 182
Cowpox, 2, 47, 232, 244
Coxiella burnetii, 2, 177
CPE. See Center for Product Evaluation
Cpg motif, defined, 73
Cpg oligonucleotides, 100
Cpgs, 146
CPRD. See Clinical Practice Research Datalink
CR, 249
CRM197 protein, 168, 169, 204
CROs. See Contract research organizations
CRS. See Congenital rubella syndrome
Crucell, 196
Cryptobia salmositica, 190
CSF. See Classical swine fever
CT. See Cholera toxin
CTD. See Common Technical Document
CTN. See Clinical trials notification
Cutter Incident (1955), 11, 52, 166, 215, 338
Cutter Laboratories (California), 11, 166, 215, 216
CVB. See Center for Veterinary Biologics
CVJE. See ChimeriVax-Japanese encephalitis
CVM. See Committee for Veterinary Medicinal Products
CXCL12, 82
CXCR4, 82
Cystitis, 60
Cytokines, 63, 116t
Cytoscape, 120t
Cytosine-phosphate-guanosine (CpG) oligonucleotides, 104
DAMAGE-ASSOCIATED MOLECULAR PATTERNS (DAMPS), 149
Daptacel, 281
Data and safety plan, 261
Data from studies, GLP regulations and, 209–210
Data monitoring committee, 261
Data safety monitoring board, 39, 261
Day-care centers, vaccine mandates for, 340
DBAP. See Division of Bacterial, Parasitic, and Allergenic Products
DBS. See Division of Biological Standards
DC-SIGN, defined, 76
DEC205, 148
Decade of Vaccines, 328–329
Decision making
cognitive biases in, 344–347
groups and peers and, 343–344
health care, models in, 341–343
vaccine common biases and heuristics applied to, 346–347
effect of ecological systems on, 344t
preferred cognitive styles applied to, 347–349, 348t
rationale for understanding psychology of, 341
stages of change applied to, 342t
Decisionally impaired individuals, institutional review board and, 271
Delayed effects, 223
Delayed type hypersensitivity, 188
Delivery service, for vaccines across the world, 248
Democratic Republic of Congo, fears about origin of HIV and oral polio vaccine trials in, 299–300
Dendritic cells, 63, 79, 102, 149, 197
adaptive immune responses in gut mucosa and, 87
antigen presentation by, 147
defined, 77
enhanced antigen uptake by, 148
innate immunity and, 77–78
Dengue shock syndrome, 137
Dengue virus (DENV), 67, 137
Denialist cognitive style, applied to vaccine decision making, 348t
Department of Health and Human Services, 265, 266, 274
“Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products” (Q5D), 256
Dermatome, herpes zoster rash in distribution of, 18, 19
Dermatophytosis, 188
Determinants, of infectious diseases, 304
Deterministic models, 314, 315
Developed countries, vaccine development and, 320
Developing countries, vaccine development and, 320
Developing Countries Vaccine Manufacturers Network, 323, 332
Developing Countries Vaccine Regulators Network, 332
DHHS. See Department of Health and Human Services
Diafiltration, 205
Diarrhea, rotavirus, 30, 31
Diphtheria, 2, 62, 68–69, 88, 178, 275, 320
Missouri epidemic, 1901, 5
mortality from, 4
prevalence of, 4–5
symptoms of, 4
value of herd immunity threshold for, 313t
values of $R_0$ for, 312t
Diphtheria, tetanus, acellular pertussis vaccine. See DTaP
Diphtheria toxin, mechanisms of vaccine-induced protection against, 90
Diphtheria toxin and antiserum (TaT), 5
Diphtheria toxoid vaccine, quality control testing for, 250
Diphtheria vaccines, 167
potency assays with recommended human vaccine dose, 202t
Diploid cell line. See Chicken embryo fibroblasts
Direct contact, transmission by, 306
Direct effects, 223
Direction de la Pharmacie et du Médicament (Senegal), 332
Disease
distinguishing between stages of infection and, 307
infection and, 306, 307
mechanisms of and comparative pathogenesis, 110–112
multi-segment viruses, 113
overlapping areas of research, 112–113
Disease surveillance, 337–338
Distinguish vaccinated from infected animals, 114, 185
Distribution of infectious diseases, 304
of vaccines, good distribution and supply practices, 257
DIVA. See Distinguish vaccinated from infected animals
Division of Bacterial, Parasitic, and Allergenic Products, within CBER, 220
Division of Biological Standards, 216
Division of Biologics Control, 216
Division of Vaccines and Related Product Applications, within CBER, 220, 221
Division of Viral Products, within CBER, 220
DMC. See Data monitoring committee
DNA vaccines, 143, 150, 155, 171–172
defined, 116, 153
for fish, 189, 190
in veterinary medicine, 185
DNA viruses, 130–133
adeno-associated viruses, 132–133
adenoviruses, 132
poxviruses, 130–132
Document Control Center, 221
Dogs
bacterial vaccines for, 186t
inactivated dermatophyte vaccines for, 188
protozoal vaccines for, 187t
second- and third-generation licensed/commercialized viral vaccines for, 185t
viruses of global importance in, 184t
DOI. See Duration of immunity
Dosages/dosing regimens
influenza vaccine, 163
phase II clinical trials and, 218
vaccination regimens for children and, 281
vaccines, 161
Dossier, 237, 238
Dot-blot assay, 250
Double-blinded studies, 264
Downstream processes, 200–202, 210
purification of vaccine antigen, 200–201
testing of vaccine potency and immunogenicity, 201–202
DPT vaccine, 167
Drinker, Phillip, 10
Droplet spread transmission, of infectious agents, 306
Drug Controller General of India, 332
Drug development process, 213
DryVAX, 176
CISA study on telephone surveillance to evaluate adverse events related to, 295–296
serious adverse events related to, 90–91
DSMB. See Data safety monitoring board
DSMP. See Data and safety plan
DTaP. See Acellular pertussis vaccines
DTaP-IPV-HBV vaccine, 250
DTH. See Delayed type hypersensitivity
DTP vaccine, injury claims against, 339
Duration of immunity, 237
studies in Australia, 239
Duration of infectiousness, of infectious agent, 309
DVP. See Division of Viral Products
DVRPA. See Division of Vaccines and Related Product Applications
Eagle MEM modified medium, 247
Eastern equine encephalitis virus, 61
Ebola virus, 113
values of $R_0$ for, 312
EC. See European Commission
ECACC. See European Collection of Cell Cultures
Ecological systems theory (Bronfenbrenner), 341, 343, 349
applied to vaccine decision making, 344
Economics of vaccine development, 326
cCTD. See Electronic Common Technical Document
Extremelia virus, 117
Edema factor, 176
Edmonston strain, of measles virus, 205, 251
Education about vaccines, 341
health care policy and, 338, 339
21st-century vaccine education, broad tasks in, 349
EEA-EFTA. See European Economic Area European Free Trade Association
EF. See Edema factor
Effective reproductive number ($R$), 311
defined, 311
formula for, 312
Effectort T lymphocytes, 80
Efficacy defined, 236
vaccine approval and, 33
clinical trials, 39
definition of, 35
veterinary vaccines and, 236, 242
EGE. See European Group on Ethics in Science and New Technologies
Egyptian Drug Authority, 332
Ehrlichia spp., 67
Ehrlichiae, 61
Eight-plasmid reverse-genetics system, 164
ELA. See Establishment License Application
Electronic Common Technical Document, 225, 226, 227, 229
Electrophoresis, 250
Electroporation, 171
Elimination, defined, 45
ELISA. See Enzyme-linked immunosorbent assay
EMA. See European Medicines Agency
Emergency use authorization, 42
Emerging infectious diseases, defined, 239
Emotion, vaccine education and, 349
Emulsions, 99–100
ENCePP. See European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
Enders, John, 10, 13, 251
Enders-Edmonston B strain, of meases virus, 251
Engerix-B, 281
England, pertussis attack rate in, 8
Enteric diseases, for vaccine research and development, 321
Enterohemorrhagic E. coli (EHEC) infection, 186
Environment, infectious, 304, 305, 305
Environmental factors, types of, 305–306
Environmental risk assessment, 223–224
of genetically manipulated organisms, 333
principles and objectives in, 223–224
procedure for, 224
scope, 223
Enzyme-linked immunosorbent assay, 124, 201, 250
EPI. See Expanded Programme on Immunization
EPIA. See European Federation of Pharmaceutical Industries and Associations
Epidemiologic surveillance, 337–338
Epidemiologic triad, 304, 305
Epidemiology, 193
Epidermophyton, 188
Epitope mapping techniques, 139
Epitopes, vaccine antigens and, 197
EPPAA. See European Partnership to Promote Alternative Approaches to Animal Testing
Equine diphtheria antiserum, 5
Equine influenza virus, 132
Equipment validation, 209
Equitable access, 340
ERA. See Environmental risk assessment
Index

Eradication
defined, 45
of disease by vaccination, 44, 178
foot-and-mouth disease, 57
infectious diseases, examples of, 323
measles, 54–55, 178, 178
other possible targets for, 57
poliomyelitis, 51, 53, 109, 178, 178
rinderpest, 51, 109, 184, 324
smallpox, 47, 48–49, 90, 109, 178, 178
Other possible targets for, 57

ErB2, 115
Escape mutants, 115

Escherichia coli, 86, 88, 143, 186
Escherichia coli O157:H7, promising vaccines for, 187
Escherichia coli O104:H4 outbreak, Germany (2011), 186

Establishment License Application, 291
Ethical issues
clinical trials and, 265
in vaccination, 350–353
exemptions from required school-entry immunizations, 352
imminent risk of serious harm, 350–351
at intersection of knowledge and values, 353
overview of, 350
parental refusal of childhood immunizations, 350
personal belief exemptions debate, 352–353
vaccine-hesitant parents, 351–352

EU. See European Union
EU Clinical Trials, 267
“EU Requirements for Batches with Maximum and Minimum Titer or Batch Potency for Developmental Safety and Efficacy Studies,” 238

EUA. See Emergency use authorization
EudraVigilance, defined, 296
European Centers for Disease Control and Prevention, travelers’ vaccines website, 325
European Collection of Cell Cultures, 199

European Commission, 237, 265, 266, 268
Directorate General for Health and Consumers, 292
good manufacturing provisions for biological products, 256
European Economic Area European Free Trade Association, 265, 268
European Federation of Pharmaceutical Industries and Associations, 268
European Group on Ethics in Science and New Technologies, 265, 266
European Medicines Agency, 36, 96, 97, 198, 200, 227–228, 237, 256, 264, 265, 266, 267, 272, 273, 296, 332, 333
Centralized Procedure, 227
Decentralized Procedure, 228
key role in approval of medicines, 228
Mutual Recognition Procedure, 227
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 296
European Parliament, 265, 266
European Partnership to Promote Alternative Approaches to Animal Testing, 239
European Pharmacopoeia, 237, 238, 239, 256
European Union, 186, 228, 257, 273, 296
clinical research regulation in, 265, 266
veterinary vaccine regulations in, 237–238
Excipients, vaccine, 156, 157
Exosystem level, vaccine decision making and, 344t
Exotic animal disease agents, 241–242
Exotic pets, vaccine recommendations for owners of, 285
Exotoxin-producing bacteria, mechanisms of vaccine-induced protection against, 90
Expanded Programme on Immunization, 297
Expert Committee on Biological Standards (WHO), 36

Exploratory stage, in vaccine development, 288
External institutional review boards, 270
Extinction, defined, 45
Extracellular microbes, 67
Extracellular pathogens defined, 144
DNA vaccine carriers and, 143
primary immune mechanisms against, 68

Factor H binding proteins, 173, 174
Family/household vaccination, 156
FAO. See Food and Agriculture Organization
“Fast track” vaccine development, 41–42, 222
FD&C. See Federal Food, Drug and Cosmetic Act
Fear-based cognitive style, applied to vaccine decision making, 348t
Fears about vaccines
autism and MMR vaccine, 298–299
cancer and vaccines, 299
mad cow disease and vaccines, 298
oral polio trials in Belgian Congo and origins of HIV, 299–300
Fever, live attenuated vaccines and, 162

Federal Food, Drug and Cosmetic Act, 213
Feline immunodeficiency virus, 137, 138
Feline leukemia virus, 132
Fendrix, 105
Fetal bovine serum, 298
FHA. See Filamentous hemagglutinin fHBP. See Factor H binding protein
Filamentous hemagglutinin, 146
Filamentous hemagglutinin, 166
Fimbriae (FIM) type 2 and type 3, 166
Findlay, Carlos, 8
First-generation vaccine, defined, 183
First-time in humans, 219
Fish
bacterial vaccines for, 186t
immunization of, 189
social and economic importance of, 189
vaccine status for, 188–190

367
Index

FIV. See Feline immunodeficiency virus
Flagellin, 105
Flaviviruses, 90, 137, 173
structure of, 138
Flocculation test, 281
FluMist, 86
FMD. See Foot-and-mouth disease
FMDV. See Food-and-mouth disease virus
Follow-up studies, 293
Food and Agriculture Organization, 51, 189, 324, 330–331
Food and Drug Act (1936), 339
Food and Drug Administration, 35, 36, 96, 172, 198, 200, 210, 213, 214, 264, 272, 285, 332
acellular pertussis vaccines licensed by, 7
alternative pathways to vaccines licensure, 41–42
Animal Rule, 221–222
Biologics License Application and, 40
Center for Biologics Evaluation and Research, 5, 11, 213, 214, 250, 265, 266, 323, 333, 338
IND review process, 219–221
Center for Drug Evaluation and Review, 213, 214
Center for Veterinary Biologics, 333
clinical trials intended for submission to, 39
Form 1572 and, 270
GLP regulations, 208
guidance documents related to vaccine development, 40–41
“Guidance to Industry,” 256
investigational new drug (IND) application and, 38, 196, 266, 288
PASS and, 293
“Points to Consider,” 256
priority review, 223
regulation of biologics and, 214, 216
regulatory approval and licensure and, 213
serious adverse events defined by, 331
30-day review clock, 221
vaccine approval process, 291
vaccine licensure and, 273
Food-and-mouth disease virus, 55
Food-borne pathogens, CDC on, 186
Food-borne transmission, of infectious agents, 306
Food-producing animals defined, 183, 233
potential emerging zoonotic diseases in, 242
vaccine selection for, 181–183
Food Security Act, 234
Foot-and-mouth disease, 184–185, 240
burden of disease associated with, 57
burning of slaughtered livestock for preventing spread of, 56
cause and transmission of, 55
FMD-free countries, 56
in UK, 114
vaccination and, 55–57
Form 1572, investigators and, 270
Formaldehyde, 258
Formalin, 156
4CMenB vaccine, 173, 174
Fowl cholera, 232
Fowlpox vectors, 131
Fragment crystalline of antibody molecule (Fc), 67
Francisella tularensis, 143, 177
Franklin, Benjamin, 1
Frost, Wade Hampton, 10
Fungi, veterinary vaccines against, 188
Fur animals, second- and third-generation licensed/commercialized viral vaccines for, 185t
Furunculosis, 189, 233
GACVS. See Global Advisory Committee on Vaccine Safety
Gardasil, 233, 326
Gastrointestinal infections, 60
GAVI. See Global Alliance for Vaccines and Immunization
GCC. See Gulf Cooperation Council
GCCPs. See Good cell culture practices
GCG. See Global Cooperation Group
GCHD. See Grass carp hemorrhagic disease
GCP. See Good clinical practice
“General Principles” statement, FDA/EMA issuance of, 273
Generation Rescue, 345–346
Generic vaccines, lack of, 178–179
Genetic reassortment, 163, 164
Genetic vaccination, 143–144
Genetically manipulated organisms, international regulation of, 333
Genetically modified organism (GMO) vaccines, environmental risk analysis for release of, 224t
Genetically modified organisms, 223
Genital warts, human papillomaviruses and, 26
Genome-wide association study, 124
Genomes, 118f, 119
hybrid, 110
GIVS. See Global Immunization Vision and Strategy
GlaxoSmithKline, 196, 281, 289, 326
Glioma, tumor vaccines against, 135
Global Advisory Committee on Vaccine Safety, 331
Global Alliance for Vaccines and Immunization, 44, 327–328
Global Consultation on the Feasibility of Measles Eradication, 55
Global Cooperation Group, 268
Global Immunization Vision and Strategy, 329–330
Global perspective on vaccines, 319–334
diseases for vaccine research and development, 321t–322t
economics of vaccine development, 326
eradication of infectious diseases, 323–324
future challenges with, 333
implementation, 324–325
major infectious diseases in world, 326–327
meningitis vaccine project, 323
private-public partnerships, 327–330
regulatory requirements, 331–333
genetically manipulated organisms, 333
national regulatory authorities, 332–333
vaccine safety, 331–332
for veterinary vaccines, 333
routine immunizations, 325
travelers’ vaccines, 325
vaccines, 330–331
Global Polio Eradication Program (WHA), 53
Global Rinderpest Eradication Program, 51
Global Training Network on Vaccine Quality (WHO), 332
Global vaccine development
diseases for, 321t–322t
major factors pertaining to, 320
priority areas R&D, new or improved vaccines, 322t
priority diseases for, 320–323
Globalization, infectious diseases and, 239, 240
GLP. See Good laboratory practice
Glucome, 118t
Glycoconjugate vaccines, 168
Glycoproteins, 66
GM-CSF. See Granulocyte-macrophage colony-stimulating factor
GM1 ganglioside receptor, 106
GMOS. See Genetically manipulated organisms; Genetically modified organisms
GMP. See Good manufacturing practice
Golden hamster, as model for yellow fever virus disease, 207
Gonorrhea, 305
SIR model and, 316
Good cell culture practices, 256–257
Good clinical practice, 37, 39, 209, 212, 267, 268, 272
Good distribution and supply practices, 257
Good laboratory practice, 36, 37, 199, 207–210, 267
animal studies and, 212
defined, 198, 213
Good manufacturing practice, 37, 198, 267, 332
in Australia, 239
Biologics License Application and, 40
defined, 201, 236
recombinant HPV VLP vaccines and, 256
vaccines and, 234
Government
disease surveillance and, 337–338
jurisdiction over clinical trials, 265–266
product regulation and, 338
Gram-negative display systems, 140–141
Gram-positive display systems, classification of, 141–142
Granulocyte-macrophage colony-stimulating factor, 179
Grass carp hemorrhagic disease, 190
Graves’ disease, 294
GREP. See Global Rinderpest Eradication Program
Group A streptococcus, 17
Group B meningococcus vaccine, reverse vaccinology and, 122
Groups, decision making and, 343–344
GSK. See GlaxoSmithKline
Guillain-Barré syndrome, RCA study of Menectra and, 295
Gulf Cooperation Council, 268
Gut mucosa, development and retention of adaptive immune responses in, 87
GWAS. See Genome-wide association study
HA. See Hemagglutinin
*Haemophilus influenzae*, 27, 84, 283
invasive disease, in United States, 1987–1997, 21
*Haemophilus influenzae* type b
(Hib), 19, 20–21, 45, 88, 168, 244, 276, 327
*Haemophilus* spp., 67
Hamster kidney cells, primary, 157
Handley, J. B., 345
HapMap project, 125
Harvested virus fluids, measles, 252
Hashimoto thyroiditis, 294
HAV. See Hepatitis A virus
HBIG. See Hepatitis B immunoglobulin
HBM. See Health belief model
HBsAg. See Hepatitis B surface antigen
HBV. See Hepatitis B virus
Health belief model, 341
Health Canada, 228–229, 268
Health Insurance Plans, 295
Healthcare workers, vaccine recommendations for, 285
Healthy People 2010 vaccine goals, 349
Heat labile enterotoxin *E. coli*, 105
HEK 293, 249, 250
Hemagglutination, 202
Hemagglutinin, 164, 165, 170, 205
Hemagglutinin (HA) protein, 114
Hemolytic uremic syndrome, 186
Hepatitis A vaccine, 25–26
potency assays with recommended human vaccine dose, 202t
for travelers, 284, 284t
Hepatitis A virus, 25, 320
liver as target organ for, 61
as possible target for eradication by vaccination, 57
vaccines and eradicaibility of, 178t
Hepatitis B immunoglobulin, 24
Hepatitis B surface antigen, 24, 71, 110, 252
Hepatitis B vaccine, 24, 327
determining potency of, 201–202
manufacturing process for, 252
potency assays with recommended human vaccine dose, 202t
recombinant, 170
recommendations for, 24
VSD study on risk of autoimmune thyroid disease and, 294
Hepatitis B virus, 24, 65, 307
liver as target organ for, 61
as possible target for eradication by vaccination, 57, 178t, 323
sexually transmitted, influences on basic reproductive number for, 312
subunit vaccines and, 71
transmission of, 24
vectors, 139
Hepatitis C, 114
Hepatitis delta virus, liver as target organ for, 61
Hepatitis E vaccine, recombinant, 171
Hepatitis E virus, 171
liver as target organ for, 61
Index

Hepatitis viruses. vaccines for, 23–26
research and development, 321
Herd immunity, 58, 264, 312–313,
336–337, 352
defined, 45, 301, 312, 336
formula for, 313
measles virus and, 313
oral polio vaccine and, 11
vaccination and, 45
Herd immunity threshold, 312, 318
basic reproductive number and,
313
values of, for well-known
diseases, 313
Horses
bacterial vaccines for, 186
inactivated dermatophyte vaccines
for, 188
protozoal vaccines for, 187
second- and third-generation
licensed/commercialized viral
vaccines for, 185
dalties of global importance
in, 184
Host, 59
as agent and carrier, 307
infectious, 304, 305
characteristics of, 305
microbe infection of, 60
Host defenses
evasion of, 72
pathogen evasion of, 65–67, 66
Host memory immune response, 153
Host restriction, 125
HPV. See Human papillomavirus
HPV recombinant vaccine,
170–171, 250
HPV recombinant vaccine,
quadrivalent (HPV4), 26
HREC. See Human Research
Committee
Hsp60, 141
H3N2, 28, 250
Human immunodeficiency virus, 67,
192
fears about oral polio vaccine trials
in Belgian Congo and origin
of, 299–300
latent and incubation periods
with, 307
vaccine recommendations
and, 282, 283–284
values of R0 for, 312
Human immunodeficiency virus type
1, 137, 138
Human immunoglobulins,
characteristics of, 85
Human papillomavirus, 60, 170,
320
Human papillomavirus vaccines, 26,
88, 113, 146, 233, 244, 263, 338
licensed indication and usage
for, 274
recombinant, 170–171, 250
Human Research Ethics
Committee, 266, 267
Human studies, IND application,
previous human experience, 219
Human subjects
clinical studies with, phase I–III
trials, 289
clinical trials and protection of, 39
institutional review board and, 271
Human-to-human transmission, of
infectious agents, 306
Human vaccine development,
veterinary vaccine development
and, 233
Humoral host defenses, elements
of, 63
HUS. See Hemolytic uremic syndrome
HVFIs. See Harvested virus fluids
Hybrid genomes or plasmids, 110
Hygienic Laboratory, 339
Hypersensitivity, 157, 162
IB. See Investigator’s Brochure
IBR. See Infectious bovine
rhinotracheitis
ICAM-1, 179
ICD protease activating factor, 105
ICH. See International Conference on
Harmonisation
“Identify, inactivate, inject”
paradigm, 109, 110
IEC. See Independent Ethics
Committee
IFFIm. See International Finance
Facility for Immunization
IFPMA. See International Federation
of Pharmaceutical Manufacturers
and Associations
IgA, 84, 85–86, 197
IgD, 84, 197
IgE, 84, 197
IgG, 84, 197
IgG1, 84
IgG2, 84
IgG3, 84
IgM, 84, 197
IIHR. See International Health
Regulations
Immediate effects, 223
Imiquimod, 105
Immune stimulating complexes, 102
Immunity
active, 305
lifelong, 46
new understanding of, 19th
century, 2
passive, 305
protective, 305, 324
Immunization. See also Vaccination
active, 153, 154
with aluminum salt-containing
vaccines, 98
booster, 156–157
catalog of policy recommendations
for, 330
CISA study on recurrent sterile
abscesses after, 296
maternal, 156
passive, 115, 154
prophylactic, 114, 153
required school-entry, exemptions
from, 352
ring, 156, 282
routine, in developing
countries, 325
tetanus toxoid, 6
therapeutic, 153
transdermal, 157
use of term, 153
WHO-recommended chart for
(2014), 276
yellow fever, 9–10
Immunization Monitoring
Program-Active, 292
Immunization safety,
monitoring, 291–292
Immunization Safety BioBank, 295
Immunization schedules
recommendations for, 340
catch-up for persons aged 4
months through 18 years
who start late or are one
month behind–U.S.,
2014, 280
for persons aged 0 through 18
years–U.S., 2014, 278
Immunocompetence, altered, vaccine
recommendations and, 282–283, 286
Immunocompromised people, 153
Immunogenicity, 305
adjuvants and increase in, 95
combination vaccines and, 174
defined, 197
live and inactivated vaccines
and, 176
testing of, 201–202
vaccine approval and, 33
clinical trials, 39
definition of, 35
Immunogens, vaccine, 155
Immunoglobulins
available for passive
immunization, 154
defined, 197
human, characteristics of, 85
Immunological veterinary medicinal
product, 234
Immunology, 110, 193
Immunone, 118
Immunosenescence, 153, 282
Immunostimulatory adjuvants, 102, 104
immunogenicity of vaccine
formulated with, 103
Immunosuppression, 153
live attenuated vaccines and, 162
Immunotherapeutic biomaterials, 150
IMPACT. See Immunization
Monitoring Program-Active
in silico experiments, defined, 120
in vitro assays, 36
in vitro experiments, defined, 120
in vivo experiments, defined, 120
Inactivated purified virus,
manufacturing process and
vaccine examples, 248
Inactivated vaccines, 2, 156, 161, 165–166
advantages with, 165–166
bacterial, in veterinary
medicine, 186
Cutter Incident and, 11, 52, 166, 215, 338
defined, 153
dermatophyte, 188
doses and routes of administration
for, 158–159
examples of, 154, 166
influenza, 29–30, 201
polio, 52, 53, 176, 205
in veterinary medicine, 184
Incidence studies, 293
Incubation period, 307
IND. See Investigational new drug
IND application. See Investigational
new drug (IND) application
Independent Ethics Committee, 267, 270–271, 272
Indian Health Service, 275
Indirect contact, transmission by, 306
Indirect effects, 223
Individual freedom, protecting
public’s health and, 350
Infantile paralysis, 10
Infants, vaccine recommendations
for, 277, 281
Infection
defined, 60, 71
disease and, 306, 307
distinguishing between stages of
disease and, 307
“iceberg” of, 111, 111, 123–124
pathogen and host response
mediated tissue damage
during, 65
subclinical, 60
Infectious agents
routes of spread in the body,
60–61
target organs and cells, 61–62
Infectious bovine rhinotracheitis, 185
Infectious disease
transmission, 304–318
characteristics of infectious agents,
hosts, and
environments, 305–306
concepts of, 304–307
epidemiologic triad in, 304
measures of, 308–313
basic reproductive number
($R_0$), 310–312
herd immunity, 312–313
transmission probability ($\beta$) and
secondary attack
rate, 308–310
modes of, 306
natural history, 306–307
Infectious diseases
in companion and food-producing
animals, vaccines for, 183
control of, in 20th century, 2–4
emerging
defined, 239
zoonotic pathogens and, 240, 240
eradicable
with vaccination, examples
of, 323
vaccines for, 178
future challenges related to, 333
Infectious diseases (cont’d)
major, in the world, 326–327
modeling, 314–316, 318
MIDAS, 314
model types, 314
SIR model, 315–316, 317
new understanding of, 19th
century, 2
pathogenesis of, 59–60
preventive vaccines, properties
of, 4t
stages of infectiousness, 307
symptoms and signs of, 60
vaccines for, 67–68
WHO on impact of, 239
Infectious hematopoietic necrosis
(IHN) virus, in salmon, 185, 185t
Infectious pancreatic necrosis, 190
Infectivity, 305
Infl ammasome complex, 77
Inflammation, at site of infection
initiated by complement
activation, 64
Infl ammatory cascade, during
sepsis, 64
Infl uenza, 27–28, 44, 88, 192, 305,
320, 336
cocooning recommended for, 282
complications from, 27
immunosenesence and, 282
multi-segment nature of, 111
pandemic, 28
1918, 28
2009–2010, 28, 29
seasonal, 27
transmission of, 27–28
values of R0 for, 312t
Infl uenza A, 27, 28, 67, 163, 250
Infl uenza A type H1N1, 28
Infl uenza A type H1N2, 28
Infl uenza B, 27, 163, 250
Infl uenza C, 27
Infl uenza vaccines, 28–30, 349
decisions around annual infl uenza
strains to include in, 258
dose and adjuvant or no
adjuvant, 163
inactivated, 29–30
development and production
of, 205
live attenuated, 30
manufacturing process for, 250
potency assays with recommended
human vaccine dose, 202t
recombinant, 171
reverse genetics applied to, 165
safety monitoring of, 96–97
seasonal manufacturing time
line, 258, 259
Infl uenza virus drift, 258
Infl uenza meningitis, relation of age
incidence of, to bactericidal
power or human blood at
different ages against smooth
meningeal strain or B.
infl uenzae, 20
Informational infl uence, 344
applied to vaccine decision
making, 347t
Informed consent, institutional review
board and, 271
Ingenuity Pathways Analysis, 120t
Initiative for Vaccine Research, 329
Injury compensation, government
and, 339
Inmate immune response, 67
Inmate immunity
activating, strategies for, 149
bridging adaptive immunity
and, 77–78
induction of, 74–77
C-type lectin receptors, 77
NOD-like receptors, 76–77
RIG-I-like receptors, 76
toll-like receptors, 75–76
Innumerate cognitive style, applied to
vaccine decision making, 348t
Insect cell lines, recombinant HPV
VLP vaccines and control of, 255
Inspections, of vaccine manufacturing
facilities, 291
Intracellular bacteria, mechanisms
used by, 67–68
Intracellular pathogens, primary
immune mechanisms against, 68
Intracytosolic pathogens
defined, 144
DNA vaccine carriers and, 143
Intradermal (ID) route of
administration, 157
Intramuscular (IM) route of
administration, 157
Intraphagosomal pathogens
defined, 144
DNA vaccine carriers and, 143
Intussusception, 171, 263
following receipt of rotavirus
vaccine, 289, 292
RCA study of RotaTeq and, 295
summary of vaccine safety trials
with emphasis on, after receipt
of rotavirus vaccine candidate
or control, 290t
Invasin, 140, 141
Invasive pneumococcal disease, 21
“Inverted pathogenicity,” for vaccine purposes, 140
Investigational new drug, 40, 267–268
Investigational new drug (IND) application, 34, 38, 39, 194, 196, 214, 229, 266, 288, 289
animal immunology and toxicology studies, 217
CBER review process, 219–221
clinical protocols and investigator information, 216
content and format of, 217–219
chemistry manufacturing and controls (CMC) information, 218–219
clinical protocol, 217–218
introductory statement and general investigational plan, 217
Investigator’s Brochure, 217, 266–267
pharmacology and toxicology data, 219
previous human experience, 219
defined, 213, 216
Form 1571 in, 220
manufacturing information, 216–217
role of, 216
30-day review clock, 221
Investigational new drug number, issuance of, 267
Investigational new drug process, clinical trials and, 266–267
Investigational new drug status, attaining, 261
Investigational vaccine, defined, 262
Investigators, 272
clinical trials, 261
defined, 262
responsibilities of, 269–270
Investigator’s Brochure, 217, 266–267
defined, 267
sponsors and maintenance of, 269
Iowa, measles in, 1960–1989, 14
IPAF. See ICD protease activating factor
IPD. See Invasive pneumococcal disease
IPN. See Infectious pancreatic necrosis
IPV. See Inactivated polio vaccine
IRBs. See Institutional review boards
Iron lung respirator, invention of, 10
ISCOMATRIX, 102
ISCOMS. See Immune stimulating complexes
Isoelectric focusing, 250
IVR. See Initiative for Vaccine Research
Jacobson, Henning, 350
Jacobson v. Massachusetts, 350, 352
Japan clinical trials in, 265
opt-in immunization policy in, 275
Japan Pharmaceutical Manufacturers Association, 268
Japanese encephalitis, 61, 113, 137, 275, 320, 325
Japanese encephalitis vaccine, for travelers, 284, 284f
Japanese Health Policy Bureau, 228
Japanese Ministry of Health, Labor and Welfare, 228, 265, 266, 268, 273
Japanese Pharmaceutical Affairs and Food Sanitation Council, 265, 266
Japanese Pharmaceutical Affairs Law, 265
Japanese Pharmaceutical and Food Safety Bureau, 228
Japanese Pharmaceutical and Medical Safety Bureau, 332
Japanese Pharmaceuticals and Medical Devices Agency, 228, 256, 265, 266, 273
JCVI. See Joint Committee on Vaccination and Immunisation
JE. See Japanese encephalitis
Jenner, Edward, 2, 47, 73, 124, 232, 244, 340
Jesty, Benjamin, 2
Joint Committee on Vaccination and Immunisation (UK), 275
Joint Program 15, 51
Journal of the American Medical Association, 301
JPMA. See Japan Pharmaceutical Manufacturers Association
Junk science, 342
Karolinska Institute, 299
KEGG (Kyoto Encyclopedia of Genes and Genomes), 120f
Kidney infection, 61
Killed pathogen vaccines epidemic louse-borne typhus and, 70
rabies and, 70
respiratory syncytial virus and, 70
Killed virus vaccines, 2, 156, 184
Killed viruses or bacteria, 67, 155
Kinome, 118f
Koplik’s spots, measles and, 13, 54
Korean Office for Health and Medical Care Policy, 332
L. lactis, proteinase PrtP of, 141
Labeling of vaccines, good distribution and supply practices and, 257
Laboratory of Biologics Control (NIH), 216
Lactobacillus plantarum, 141
LAIV. See Live attenuated influenza vaccine
LambA, 140
Landsteiner, Karl, 10
Lassa fever, 111
Lassa virus, 137
Latent period, 306–307
Layer-by-layer assemble, 146
Layered DNA-RNA vectors, 134
Lazear, Jesse, 8
Leningrad-16 measles strain, 251
Leptiviruses, 137–139
Leptospira interrogans, 141
Lethal factor, 177
Leukocyte functional antigen-1, defined, 78
LF. See Lethal factor
Lf units, meaning of, 281
LFA-1. See Leukocyte functional antigen-1
Liability, vaccine safety and, 298
Liberty-public health tension, 350
Licensed indications recommendations compared with, 274
usage and, 273, 274
Licensed vaccines for humans, 152–179
immunization strategies, 153–157, 161
active immunization, 155–156
booster immunizations, 156–157
cell culture used to prepare vaccines, 157
cocooning, 156
dosing regimen, 161
hypersensitivity, 157
maternal immunization, 156
mucosal-based vaccine, 161
overview, 153–154
passive immunization, 154–155
ring immunization, 156
route of administration, 157
vaccine excipients, 157

Licensure of vaccines, 35–36, 195
alternate strategies for, 41–42, 221–223
accelerated approval, 222–223
“Animal Rule,” 221–222
fast track, 222
priority review, 223
clinical trials and, 214
global pathways for, 273
international regulatory requirements
for genetically manipulated organisms, 333
national regulatory authorities, 332–333
vaccine safety, 331–332
for veterinary vaccines, 333
pivotal study and, 198
post-licensure activities, 41
safety monitoring after, objectives for, 288
of veterinary vaccines, 333
policies and regulations for, 234
time frame and estimated costs for, 233–234
Life expectancy, vaccines and, 3
Lifelong immunity, 46
Limit of Flocculation, defined, 281
Lipidome, 118
LipL21, 141
LipL32, 141
Lipobeads, 148
Lipo/oligosaccharide, 166
Lipopolysaccharide, 104
Liposome-based antigen delivery strategy, 148
Liposomes, 100–101, 106, 150
antigen encapsulation strategies based on, 146
local events following injection of, 101
Lister strain, 2
Listeria, 113
Listeria monocytogenes, 143, 144
Live and inactivated vaccines, 175–176
immunogenicity and, 176
market size and, 175–176
Live attenuated bacterial vaccines, in veterinary medicine, 186
Live attenuated bacterium, manufacturing process and vaccine examples, 248
Live attenuated influenza vaccines, 30
determining potency of, 201
Live attenuated organisms, 67–68
Live attenuated pathogen vaccines, 70–71
childhood viral infections, 71
epidemic louse-borne typhus, 70–71
yellow fever, 71
Live attenuated vaccines, 36, 161–163, 161
advantages and disadvantages of, 161–162
basis of, 156
decision making around receiving, 162
defined, 153
EU requirements for, 238
examples of, 154, 161
rinderpest, 50
in veterinary medicine, 183–184
Live attenuated viruses, 155
first vaccines based on, 244
manufacturing process and vaccine examples, 248
virus reassortment and, 163
Live bacterium vaccines, doses and routes of administration for, 158
Live viral vectored vaccines, in veterinary medicine, 185
Live virus vaccines
doses and routes of administration for, 158
dosing regimens for, 161
Liver, as target organ for hepatitis, 61
Liver cancer vaccine, 178
Livestock workers, vaccine recommendations for, 285
Lockjaw (tetanus), 2, 6, 68
L1 proteins, recombinant human papillomavirus vaccine and, 171
Longitudinal studies, 293
Louse-borne typhus, epidemic, 70–71
LPS. See Lipopolysaccharide
LT. See Heat labile enterotoxin E. coli
Lyme disease, 171
LYMErix, 171–172
Lymphocytes, 63
M cells (microfold cells), 86–87
Macrophages, 63, 66, 87
Macrosystem level, vaccine decision making and, 344
Mad cow disease, fears about vaccines and, 298
MadCAM-1, 86, 87
Madin-Darby canine kidney (MDCK) cells, 29, 248
MAH. See Marketing Authorization Holder
Maintenance stage of behavior change, applied to vaccine decision making, 342, 342
 Major histocompatibility complex, 77, 129, 197
Major histocompatibility complex class I, 67
Malaria, 307
value of herd immunity threshold for, 313
Managed care organizations, 293
Mandates, vaccine, 275, 340
Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 331
Manufacturing and process development, vaccine development and, 37–38
Manufacturing vaccines, 243–259
analytical aspects, 252–256
cell substrates examples of, 248–249
novel, 249–250
control of source materials, 254–256
definitions related to, 248, 249
future outlook
elimination of preservatives, 258
influenza viral drift, 258
mucosal vaccination, 258
new technologies, 257
vaccine safety, 257
good manufacturing practices, 256–257
good cell culture practices, 256–257
good distribution and supply practices, 257
manufacturing process and examples of vaccines, 248
national regulatory authorities and, 332
overview, 250
production examples, 250–252
inactivated vaccine: influenza vaccine, 251
live attenuated: measles virus vaccine, 251–252
recombinant: hepatitis B vaccine, 252
steps in, 244, 248
Marburg virus, 113
March of Dimes, 52
Mariner, Jeffrey, 50
“Marker vaccines,” 185
veterinary vaccination and, 114
Marketing Authorization Holder, 293, 297
Mass spectrometry, 118, 250
Mass vaccination, 336, 337, 340
Master cell bank, 244, 247
Master cell banks
defined, 249
recombinant HPV VLP vaccines and control of, 255
Master regulators, 120
Master seed lot, 244, 247, 249
Master vaccine strain, 163, 165
Materials sciences, 110
Maternal immunization, 156
Matther, Cotton, 1
Maximum incubation period, 308–309
MCOs. See Managed care organizations
MCV4 vaccine, 23
MDA5, 74
defined, 76
innate immunity and role of, 76
MDCK cells. See Madin-Darby canine kidney (MDCK) cells
MDP. See Muramyl dipeptide
Measles, 12–15, 136, 178, 192, 275, 301, 309, 320, 339
atypical, 14
as eradicable disease with vaccination, 323
first isolation of virus, 251
herd immunity and, 313
in Iowa, 1960–1989, 14
mortality rate from, 12–13
population-based vaccination programs and, 336
protective immunity and, 305
rash related to, 13
SIR model and, 316
transmission and symptoms of, 12, 54
in USA, 1960–1989, 14
vaccination and, 53–55
value of herd immunity threshold for, 313
values of R0 for, 312
Measles, mumps, and rubella, 13, 15, 16, 18, 57, 71
Measles, mumps, rubella, and varicella, 13, 15, 16, 281
Measles, mumps vaccine, aseptic meningitis case report, 302
Measles epidemiics, Vaccines for Children Program in response to, 340
Measles-specific maternal antibodies, 54
Measles vaccine, 157, 337
development and production of, 205
licensure of, 14
manufacturing process for, 251–252
potency assays with recommended human vaccine dose, 202
secondary attack rate and efficacy of, 309
Media
risk perception, irrational behavior, and, 300–301
vaccine decision making and, 345
Medicaid, children eligible for, 340
Medical aid workers, vaccine recommendations for, 285
Medical exemptions, 277
Medimmune, 196
Medin, Karl Oscar, 10
Melanoma
mutated cyclin-dependent kinase 4 in, 115
tumor vaccines against, 135
Membrane, 173
Memory T cells, 80
MenA conjugate vaccine, 323
MenAfriVac, 169, 323
MenB vaccines, 173
Menectra, RCA study of Guillain-Barré syndrome and, 295
Meningitis, Hib, 20
Meningitis Vaccine Project, 323
Meningococcal A conjugate, geographic region and variation in, 323
Meningococcal bacteremia, purpura fulminans in child with, 23
Meningococcal bacteria, spread of, 61
Meningococcal conjugate quadrivalent vaccines, licensed indications and recommendations for, 274
Meningococcal disease, 320
conjugate vaccines and, 168–169
incidence of, 23
Meningococcal vaccines, 168
multivalent glyco-conjugate, 250
potency assays with recommended human vaccine dose, 202
for travelers, 284
Meningococcus, description of and complications from, 22–23
Merck, 196, 281, 289, 326
Merck-Wellcome Trust Hilleman laboratories, 327
Mesosystem level, vaccine decision making and, 344
Metabolome/metabonome, 118
MF59, 100
MF59 squalene, 257
MHC. See Major histocompatibility complex
MHC-I. See Major histocompatibility complex class I
Index
Index

MHLW. See Japanese Ministry of Health, Labor and Welfare
MI. See Motivational interviewing
Micelles, antigen encapsulation strategies based on, 146
Microarrays, 119
Microbes
host infection by, 60
modes of transmission, 59
pathogenic, routes of spread and sites of replication for, 63
Microbial diseases, vaccines for, 192–210
animal models, 206–207
nonclinical vaccine immunogenicity and efficacy, 206–207
nonclinical vaccine safety and toxicity, 207
downstream processes, 200–203
purification of vaccine antigen, 200–201
testing of vaccine potency and immunogenicity, 201–202
good laboratory practices, 207–210
identifying vaccine protective antigens, 196–197
inactivated virus vaccine development (yellow fever), 205–206
product development pathway, 195–196
upstream processes, 199–200
propagation of vaccine antigens in cell culture, 200
selection and characterization of vaccine antigen, 199–200
vaccine design principles, 193–194
vaccine development, key considerations, 193
vaccine development and production, examples, 202–205
bacterial polysaccharide (Streptococcus pneumoniae), 203–205
inactivated virus (polio), 205
inactivated virus subunits (influenza), 205
live attenuated (measles), 205
recombinant protein (hepatitis B), 203
vaccine development pathway, 198–199
Microbiology, 110
Microorganisms, pathogenic, infection by, 59
Microparticles, 101–102, 150, 189
Microsphere multiplex assays, 257
Micosporum, 188
Microsystem level, vaccine decision making and, 344
MIDAS. See Models of Infectious Disease Agent Study
Middle-income countries, vaccine development and, 320
Military personnel vaccines for protection of, 339
Minnesota, Hib in young children living in, 2008, 20–21
Minor use/minor species, 242
MMR. See Measles, mumps, and rubella
MMR vaccine, 252, 281, 282, 349
catch-up vaccination schedule for, 276
disparate recommendations for, 275
fears about autism and, 298–299, 343, 345–346
VAERS investigation of thrombocytopenic purpura and, 292
MMRV. See Measles, mumps, rubella, and varicella
MMRV vaccine, 17, 18, 252
Mode of transmission, 306, 309
Models of Infectious Disease Agent Study, 314
Modified vaccinia Ankara, 2, 130–131
Molecular biology, 110, 125, 193
recombinant vaccines and, 113–114
Monkeypox vaccine, 285
Monoclonal antibodies, passive immunization and, 155
Monocytes, 102
Monophosphoryl lipid A, 100, 104–105, 257
Monovalent seed virus, 250
Monovalent split virus concentrate, 251
Montague, Mary Wortley, 1
Montanide 720, 100
Mopeia virus, 111
Moraten strain, of measles virus, 205
Motivational interviewing, 348–349
Mousepox, 117
MPL. See Monophosphoryl lipid A
MP54 vaccine, 23
MRC-5 human fetal diploid fibroblasts, 157
MSB. See Master cell bank
MSIR model, 316, 317
MSL. See Master seed lot
MSV. See Monovalent seed virus
MSVC. See Monovalent split virus concentrate
MUC1, colonic adenomatous polyps and, 115
MucoRice, 144
Mucosal-based vaccines, 161
Mucosal sites, development of immunity at, 86–88
Mucosal surfaces adjuvants and, 107–108
IgA antibody class and protection of, 84, 85–86
Mucosal vaccination, 258
Mueller and Miller medium, 247
Multi-segment viruses, 111
Multiple antigenic peptide (MAP) display system, 146
Mumps, 15–16, 88, 192, 301, 320
as eradicable disease with vaccination, 178t, 323
SIR model and, 316
value of herd immunity threshold for, 313t
values of Ro for, 312t
Mumps virus vaccines, 16
MUMS. See Minor use/minor species
Muramyl dipeptide, 105
Muramyl tripeptide phosphatidylethanolamine, 105
Murine models, advantages with, 206
Mutated cyclin-dependent kinase 4, in melanoma, 115
Mutations, cancer and, 115
Mutual recognition procedure, 237
MVA. See Modified vaccinia Ankara
MVP. See Meningitis Vaccine Project  
MVS. See Master vaccine strain  
*Mycobacterium bovis*, 2, 3, 142, 156  
*Mycobacterium tuberculosis*, 65, 142  
Mycoplasma, quality control testing, 201t  
*Mycoplasma tuberculosis* lipoprotein  
Mb19, 141  
MyD88, defined, 76  
NA. See Neuraminidase  
NadA. See Neisserial adhesin A  
NADPH. See Nicotinamide adenine dinucleotide phosphate  
NAIP5. See NOD-like receptor proteins neuronal apoptosis inhibitory protein 5  
NALP1 protein, 77  
NALP2 protein, 77  
NALP3 protein, 77, 149  
Nanogels, 148–149  
Nanomatrix, 148  
Nanoparticles, 101–102, 150, 189 defined, 123, 148 with hydroxylated surfaces, 149  
National Association of County and City Health Officials, 275  
National Cancer Institute, Central IRB, 271  
National Centre for Immunization Research and Surveillance (Australia), 291  
National Childhood Vaccine Injury Act, 291, 339  
National control laboratories, 332  
National Foundation for Infantile Paralysis, 52  
National Health and Medical Research Council (Australia), 266, 273  
National Health System, 296  
National Immunization Committee, 275  
National immunization days, in Cuba, 53  
National Immunization Survey, 43  
National Influenza Centers, 258  
National Institute of Allergy and Infectious Diseases, 9  
National Institute for Biological Standards and Control, 199, 205  
National Institute for General Medicine and Science, 314  
National Institute of Allergy and Infectious Diseases, 11  
National Institutes of Health, 9, 199, 215–216  
Clinical Trials database, 38  
National Microbiological Institute, 216  
National regulatory authorities, 332–333, 334 licensure of candidate vaccines and, 35, 36  
National Vaccine Injury Compensation Program, 291  
National Vaccine Program Office, 275  
National Veterinary Stockpile, diseases covered with deployment of, 241  
Native American children, invasive pneumococcal disease and, 21  
Natural history of disease, 306–307  
timeline, 306  
NCIRS. See National Centre for Immunization Research and Surveillance  
NCLs. See National control laboratories  
NCVIA. See National Childhood Vaccine Injury Act  
NDA. See New Drug Application  
NDS. See New Drug Submission  
NDV. See Newcastle disease virus  
Needle inoculation, transmission through the skin and, 60  
Nef, 67  
*Neisseria* hiliar binding antigen, 174  
*Neisseria meningitidis*, 22–23, 45, 84, 167, 168, 283, 323 purified polysaccharide vaccines against, 122  
subunit vaccines and, 71  
*Neisseria meningitidis* type B candidate vaccine, development by reverse vaccinology, 174  
*Neisseria* spp., 67  
Neisserial adhesin A, 174  
Neonatal tetanus, 6, 6, 156, 323, 324  
*Necospora caninum*, 187  
Netherlands, rulella in, September 2002–2005, 16t  
Neuraminidase, 114, 164, 165, 170, 205  
Neuroscience, 110  
Neutrophilic polymorphonuclear leukocytes, 63  
New Drug Application, 225–227, 267  
Common Technical Document, 225 defined, 196, 225, 267  
electronic submissions, 225–226  
maintenance of, 227 phase IIIa studies and, 264  
submission and review of, 226–227  
New Drug Submission (Canada), 229  
New vaccine pipeline, 196  
New York Board of Health strain, 2  
Newborns, 156  
vaccine recommendations for, 277, 281, 282  
Newcastle disease virus, 135–136  
NF-kB, defined, 76  
NHBA. See Neisseria hiliar binding antigen  
NMHRC. See National Health and Medical Research Council  
NHS. See National Health System  
NIBSC. See National Institute for Biological Standards and Control  
NIC. See National Immunization Committee  
Nicotinamide adenine dinucleotide phosphate, 67–68  
NIDs. See National immunization days  
NIH. See National Institutes of Health  
Niosomes, 100  
Nipah virus, 240, 241  
NLRs. See NOD-like receptors  
NOD-like receptor proteins neuronal apoptosis inhibitory protein 5, 105  
NOD-like receptors, 149 defined, 76 innate immunity and, 76  
Nonclinical research, defined, 206  
Nonclinical safety and toxicology testing, 36  
Nonclinical stage, vaccine development, 288  
Nonclinical testing, 34, 37–38  
Nonclinical vaccines, animal models immunogenicity and efficacy, 206–207  
safety and toxicity, 207
Noncommunicable disease vaccines, 177
Noncore vaccines, for companion and food-producing animals, 182
Nongovernmental organizations, 327, 340
Noninfectious agents, vaccines against, 114–116
Noninfectious disease vaccines, 177–178
Noninfectious diseases, in companion and food-producing animals, vaccines for, 183
Normative influence, applied to vaccine decision making, 346
Novartis, 196, 326
Novartis Vaccines Institute for Global Health, 327
Novel cell substrates, CR, EB66, HEK 293, PER.C6, 249, 250
NRAs. See National regulatory authorities
NS1, 67
Nuclear magnetic imaging, 250
NVS. See National Veterinary Stockpile
NYVAC, 130, 131
Objectives, in vaccine clinical trials, 263
OBRR. See Office of Blood Research and Review
OCGT. See Office of Cellular, Tissue and Gene Therapies
OECD. See Organisation for Economic Cooperation and Development
Off-label use, 274, 285
Office for Human Research Protections, 265
Office of Biologics II (Japan), 266
Office of Blood Research and Review, 220
Office of Cellular, Tissue and Gene Therapies, 220
Office of Internationale des Epizooties, 51
Office of Scientific Evaluation (Australia), 266
Office of Vaccine Research and Review, 214, 220, 221
OHRP. See Office for Human Research Protections
OIE. See Office of Internationale des Epizooties (also known as World Organization for Animal Health)
Oil-in-water emulsions, 100, 106
Oka strain varicella vaccine, 17, 19
“-omics” technologies, overview of, 118, 118t, 119
Omission bias, applied to vaccine decision making, 347
OmpA, 140
OMPC. See Outer membrane protein complex
OmpS, 140
OMVs. See Outer membrane vesicles
Oncology, 110
Open-access software tools, 119
Open reading frame 2 (ORF2), recombinant hepatitis E vaccine and, 171
Open reading frames, 122, 173
OprF, 140
OPV. See Oral polio vaccine
Oral cancers, human papillomaviruses and, 26
Oral polio vaccine, 52, 53
live attenuated, 176
low cost of goods and, 250
trials in Belgian Congo, fears about origin of HIV and, 299–300
Oral rabies vaccine, 241
ORFs. See Open reading frames
Organisation for Economic Cooperation and Development, 36
Principles on Good Laboratory Practice, 208
Orthopoxvirus, 130
ORV. See Oral rabies vaccine
Osler, William, 340
Orthopox vectors, 132
Outcome, natural history and, 306
Outer membrane protein complex, 169
Outer membrane vesicles, 174
OVRR. See Office of Vaccine Research and Review
PA. See Protective antigen
Packaging cell lines, 134
Packaging of vaccines, good distribution and supply practices and, 257
PAES. See Post-authorization efficacy study
PAFSC. See Japanese Pharmaceutical Affairs and Food Sanitation Council
PAL. See Japanese Pharmaceutical Affairs Law
PAMPs. See Pathogen-associated molecular patterns
Pan African Rinderpest Campaign, 51
Pan American Health Organization, 48, 53
Pan American Network on Drug Regulatory Harmonization, 268
Pan American Sanitary Organization, 48
Parents
health care professional guidance for discussing childhood immunizations with, 303
refusal of childhood immunizations by, 350
vaccine-hesitant, 351–352
Parainfluenza virus type 3, 136
Paralytic poliomyelitis, 52
Parasites
slow development of, factors related to, 187
veterinary vaccines against, 187–188
Parasitic diseases, for vaccine research and development, 321
PARC. See Pan African Rinderpest Campaign
Passive immunity
artificial, 154–155
immunoglobulins available for, 154t
PASS. See Post-authorization of safety study
Passive immunity, 2, 305
Passive immunization, 115, 154t
vaccine-hesitant, 351–352
Parkinson’s disease, 114
PAP. See Prostatic acid phosphatase
Paracellular transport, defined, 147
PANDRH. See Pan American Network on Drug Regulatory Harmonization
PAP. See Prostatic acid phosphatase
Paracellular transport, defined, 147
Parainfluenza virus type 3, 136
Paralytic poliomyelitis, 52
Parasites
slow development of, factors related to, 187
veterinary vaccines against, 187–188
Parasitic diseases, for vaccine research and development, 321
PARC. See Pan African Rinderpest Campaign
Parents
health care professional guidance for discussing childhood immunizations with, 303
refusal of childhood immunizations by, 350
vaccine-hesitant, 351–352
Parkinson’s disease, 114
PASS. See Post-authorization of safety study
Passive immunity, 2, 305
Passive immunization, 115, 154t
artificial, 154–155
immunoglobulins available for, 154t

licensed vaccines for humans and, 154–155
natural, 155
reactogenicity and, 157
Passive surveillance, 291–292
defined, 291
effectiveness of, 292
Passive vaccination, defined, 114
Pasteur, Louis, 2, 70, 232, 244
Pasteurella multocida, 232
PATH. see Program for Appropriate
Technology in Health
Pathogen-associated molecular patterns, 67, 73, 74, 78, 97, 102, 104, 149
Pathogenesis, of infectious diseases, 59–60
Pathogenic microbes
portals of entry/shedding for, 61
routes of spread and sites of replication for, 63
Pathogenicity, 305
Pathogens
adhesins and, 66
evasion of host defenses by, 65–67, 66t, 72
primary and secondary T-cell responses to, 74
PathVisio, 120t
Pattern recognition receptors, 73–74, 75t, 78, 97, 102, 104, 149, 150
PBMCs. See Peripheral blood mononuclear cells
PCV2. See Porcine circovirus type 2
PCV13. See 13-valent pneumococcal conjugate vaccine
PCV7 vaccine, 21–22, 22t
PDPs. See Product development partnerships
Pediarix, 281
Pediatric disease, polysaccharide-encapsulated pathogens and, 84
Pediatric vaccines, 195
Peebles, Thomas, 251
Peers, decision making and, 343–344
PEG. See Polymer poly (ethylene-glycol)
Pentacel, 281
PEP. See Postexposure prophylaxis
Peptidome, 118t
PER.C6, 249, 250
Perinatal transmission, of infectious agents, 306
Peripheral blood mononuclear cells, 179
Peripheral route to persuasion, in context of vaccines, 345
Personal belief exemptions, debate over, 352–353
Personalized medicine, 42
Personalized vaccines/vaccinology, 123–124, 179
Persuasion, routes of, in context of vaccines, 345
Pertactin, 166
Pertussis toxin, 166
Pertussis ("whooping cough"), 2, 7–8, 88, 178, 320, 339
attack rate in England and Wales, 8
SIR model and, 316
vaccination of pregnant women against, 282
value of herd immunity threshold for, 313t
values of $R_0$ for, 312t
Peste des Petits Ruminants, 49, 57, 132
Peyer’s patches, 86, 87
Pfizer, 196, 326
PFSB. See Japanese Pharmaceutical and Food Safety Bureau
PGL. See Poly (lactide-co-glycolide)
PGLA particles. See Poly (lactic-co-glycolic acid) particles
ph-sensitive poly (beta-aminoester), 146
PHAC. See Public Health Agency of Canada
Phagocytosis, 66, 79
Pharmacological Affairs Law (Japan), Article 42-1 of, 256
Pharmacodynamics, phase I clinical trial and, 218
Pharmacoepidemiological studies, types of, 293
Pharmacokinetics, phase I clinical trial and, 218
Pharmacology and toxicology data, IND, integrated toxicology summary, 219
Pharmacovigilance, vaccine, defined, 288
Phase I clinical trials, 38, 39, 214, 218, 261, 262–263, 263t, 264, 272, 289
Phase II clinical trials, 38, 39, 214, 218, 261, 263, 263t, 264, 272, 289
Phase III clinical trials, 38, 39–40, 214, 218, 261, 263–264, 263t, 272, 289, 291
Phase IV clinical trials, 44, 261, 263t, 264, 272
defined, 218
Marketing Authorization Holder and, 293
secondary attack rate and, 309
Phenol, 258
Philadelphia, yellow fever epidemic in, 8
Phipps, Benjamin, 47
PHN. See Postherpetic neuralgia
PhoE, 140
Physical environmental factors, 305
Picornaviruses, 139
plgR. See Polymeric immunoglobulin receptor
Pigs
bacterial vaccines for, 186t
second- and third-generation licensed/commercialized viral vaccines for, 185t
viruses of global importance in, 184t
Pinocytosis, 79
Pivotal clinical trials, 264
Pivotal study, defined, 198
PKD. See Proliferative kidney disease
PLA. See Product License Application
Placebo, 264
Plague, 2
Plague vaccines, live attenuated, 177
Plant vectors, 144
Plasma cells, 197
Plasmid DNA, manufacturing process and vaccine examples, 248t
Plasmids, hybrid, 110
Plasmodium falciparum, incubation period of, 307
PLG. See Poly (lactic-co-glycoline)
PLGA. See Polymer poly (lactic-co-glycolic acid)
Plowright, Walter, 50, 184
Plowright vaccine, 50, 184
Index

PMDA. See Japanese Pharmaceutical and Medical Devices Agency  
Pneumococcal polysaccharide vaccine, multivalent, 21  
Pneumococcal vaccines, multivalent glyco-conjugate, 250  
Pneumococcus, 21, 320, 339  
Pneumonia immunosenescence and, 282  
13-valent vaccine and, 168  
Pneumonic plague, 177  
Podcasts, 349  
Poland, Caroline M., 343, 349  
Poland, Gregory A., 343, 349  
Polio/poliomyelitis, 3, 10–12, 61, 178, 192, 275, 320  
as eradicable disease with vaccination, 323, 324  
origins of, 52  
vaccination and, 51–53, 109  
value of herd immunity threshold for, 313t  
values of R0 for, 312t  
wild-type, one of the last cases of, in USA, 10  
Polio vaccine, 11  
Cutter Incident and, 11, 52, 166, 215, 338  
inactivated determining potency of, 202  
development and production of, 205  
serum and secretory antibody responses to intramuscular inoculation of, 11  
live, determining potency of, 202  
live attenuated, serum and secretory antibody responses to orally administered, 11t  
oral, 12  
potency assays with recommended human vaccine dose, 202t  
trivalent, 176  
Politics, defined, 336  
Politics in vaccinology  
disease surveillance, 337–338  
equitable access, 340  
инjury compensation, 339  
oficial recommendations, 340  
philosophical basis for, 336–337  
product regulation, 338  
vaccine mandates, 340  
Polyinosine:cytosine (poly I:C), 100  
Poly (lactic-co-glycolic acid) particles, 189  
Poly (lactide-co-glycolide), 189  
Poly (lactide-co-glycoline), 101  
Polyacrylamide gel electrophoresis, 250  
Polyanhydrides, 146  
Poly (lactile-co-glycolic acid), 145, 147, 148  
Polymer poly (ethylene-glycol), 202  
Polymer poly (lactic-co-glycolic acid), 145, 147, 148  
Polymeric immunoglobulin receptor, 84, 86  
Polypropylene sulfide nanoparticles antigen-conjugated, 148  
surface-functionalized, 149  
Polyribosylribitol phosphate, 20  
Polysaccharide bacterium vaccine, doses and routes of administration for, 160t  
Polysaccharide conjugate vaccines, 45  
Polysaccharide conjugated to carrier proteins, manufacturing process and vaccine examples, 248t  
Polysaccharide encapsulated bacteria, vaccines for, 19–20  
Polysaccharide-protein conjugate vaccines, induction of antibody responses using, 83  
Polysaccharide vaccines, 161t, 167–168, 179  
defined, 153  
examples of, 154t  
Polysaccharides, 150  
Polystyrene, 147  
Population-based vaccination programs, basis for, 336, 336t  
Population growth, 320  
Porcine circovirus type 2, chimeric vaccines for, 185  
Portals of entry for bacterial and viral pathogens, 62t  
for pathogenic microbes, 61t  
transmission and, 60  
Post-authorization efficacy study, defined, 293  
Post-authorization of safety study, defined, 293  
Postlicensure efficacy and safety, phase IV clinical trial and, 218  
Potency, vaccine assays with recommended human vaccine dose, 202t  
defined, 195, 236  
ensuring, 201  
testing of, 201–202  
vaccine approval and definition of, 35  
good manufacturing practice and, 37  
veterinary vaccines and, 236, 242  
Poultry  
bacterial vaccines for, 186t  
protozoal vaccines for, 187t  
second- and third-generation licensed/commercialized viral vaccines for, 185t  
viruses of global importance in, 184t  
Poverty vaccines, 35  
Poxvirus-vectored rabies vaccine, 132  
Poxviruses, 113, 130–132  
structure of, 131t  
PPP. See Private-public partnerships  
PPR. See Peste des Petits Ruminants  
PPS23. See 23-valent pneumococcal polysaccharide vaccine  
Pre-contemplation stage of behavior change, applied to vaccine decision making, 342, 342t  
Preclinical testing, vaccines, 34  
Preferred cognitive styles model, vaccine decision making and, 347–349, 348t  
Pregnancy  
live attenuated vaccines and, 162t  
maternal immunization during, 156  
varicella and, 17  
Pregnant women  
institutional review board and, 271  
vaccine recommendations for, 282  
Premembrane (prM), 173
Preparation stage of behavior change, applied to vaccine decision making, 342, 342
Prequalified vaccines, United Nations, 330
Preservatives, elimination of, 258
Preventive screening, government and, 340
Prevnar, 326
Prevnar polysaccharide vaccine, development and production of, 204–205
Primary cell cultures (PriCC), 248, 249
Principal investigator, 261
Prions, 298
Priority review, 223
Prisoners, institutional review board and, 271
Private-public partnerships, 327
ProCC. See Production cell culture
Product development partnerships, 327, 333
Product development pathway, 195–196
regulatory burden in, 195

testing, 196
time and economic investment in, 196
Product License Application, 291
Production cell culture, defined, 249
Program for Appropriate Technology in Health, 323, 327, 328
Project BioShield Act, provisions of, 285
Proliferative kidney disease, 190
Prophylactic immunization, 153, 154
Prophylactic vaccination, defined, 114
Prospective cohort studies, 293
Prospective studies, 293
Prostate cancer, 135, 179
Prostate cancer vaccine, 132
Prostate-specific antigen, 113
Prostatic acid phosphatase, 179
Protective antigen, 176
Protective immunity, 73, 109, 305, 324
Protein secretion systems, 140
Proteome, 118
Proteomics, 118, 119, 121
Protocols, 267
defined, 262
institutional review board and, 271
investigators and, 270
objectives in, 261
Protozoal vaccines, veterinary, listed by target animal, 187
Provincial Medical Laboratory of Kisangani, 299–300
PRF. See Polyribosylribitol phosphate
PRRs. See Pattern recognition receptors
PSA. See Prostate-specific antigen
PSCAN, 120
Pseudomonas syringae, 141
Pseudorabies, alphavirus vectors tested in vaccines against, 135
PT. See Pertussis toxin
Public communication
government and, 338–339
public health and, 301–302

Public health
importance of vaccines in, 43, 244
individual freedom and, 350
public communication and, 301–302
veterinary vaccines in, impact of, 239–241
Public Health Agency of Canada, 298
Public Health Service, Hygienic Laboratory, 215
Public opinion, 338–339
Public-private partnerships, 333
Public Service Act, 338
Pure Food and Drugs Act, 215
Purification, new technologies in, 257
Purified polysaccharide, manufacturing process and vaccine examples, 248
Purified protein/purified protein toxoid, manufacturing process and vaccine examples, 248
Purified virus-like particles, manufacturing process and vaccine examples, 248

Purity, vaccine
defined, 195, 236
ensuring, 201
vaccine approval and definition of, 35
good manufacturing practice and, 37
veterinary vaccines and, 236, 242

Purpura fulminans, in child with meningococcal bacteremia, 23
“Push” technologies, 349
Pyrogen assay, 250
Pythium insidiosum, 188
Q fever, 2
occupational risks and, 285
Q fever vaccine, 177
QA. See Quality assurance
QAU. See Quality assurance unit
QC. See Quality control
Q11, 149
QS-21, 102, 106
QUA, 208
Quality assurance, defined, 198
Quality assurance unit, defined, 198
Quality control defined, 198
testing of viral vaccine product from harvest to filled drug product, 201, 201
of vaccine manufacturing, 250 of vaccines assays and, 253
Quarantine, 156, 352
Quil-A, 102
Rabies vaccine, 166, 244
killed pathogen, 70
for travelers, 284, 284
Rabies virus, 88, 136–137, 157, 185, 241, 320
Raboral VR-G, 130
Radial immunodiffusion, 201
Radiation, CBRN medical countermeasures against, 285
Rainbow trout, 190
Randomization, 264
Randomized, double-blinded trials, 264
Randsell Act, 215
Rapid cycle analysis (RCA) studies, examples of, 295
Rationally designed virus vaccines, in veterinary medicine, 184–185
Reactogenicity, 157
defined, 96
to veterinary vaccines, 106
REACTOME, 120
Reassortant viruses, 111, 112, 112
Recombinant BCG (rBCG), 142
Recombinant DNA-derived vaccines
advantages of, 170
hepatitis B vaccine, 170
hepatitis E vaccine, 171
human papillomavirus
vaccine, 170–171
influenza vaccine, 171
Recombinant DNA hepatitis B
vaccine, development and
production of, 203
Recombinant DNA technology, 110,
223, 333
Recombinant HBsAg vaccine. See
Hepatitis B surface antigen
Recombinant HPV VLP vaccines
antigen manufacturing process,
254
complexity and extent of required
testing for, 254–256
manufacturing compliance
with, 254
source materials control
control of cell culture
medium, 254–255
control of cell cultures for
manufacturing of
antigen, 254
control of HPV antigen
vaccine, 255
control of master and working
cell banks, 255
control of purified monovalent
antigen bulk, 255
control of recombinant
baculovirus master seeds and
working seeds, 255
control of records, retained
samples, distribution, and
labeling, 256
control on adsorbed monovalent
antigen bulk, 255
control on final vaccine
bulk, 255–256
control on final vaccine lots, 256
Recombinant subunit vaccines, 179
Recombinant vaccines, 110, 161t
defined, 153
tabular examples of, 154t
molecular biology and, 113–114
for pandemic influenza, generation
of, 164
Recombinant viruses, 125
Recommendations
disparate, case of, 275
licensed indications compared
with, 274
universal, factors considered in
making, 274t
Record keeping, GLP regulations
and, 209–210
Recurrent sterile abscesses, after
immunization, CISA study
on, 296
Red sea bream iridoviral disease.
190
Reductionism, defined, 109
Reed, Walter, 8
Regular licenses, 234
Regulatory affairs, 193
Replication competent alphavirus
vectors, 134
Replication cycle, 59
Representativeness heuristic
applied to vaccine decision
making, 346t
in context of vaccines. 345
Research
translational, 110
in vaccine development
pathway, 36–37
Reservoirs, 60, 306
Resiquimod, 105
Respiratory diseases, for vaccine
research and development, 321t
Respiratory infections, person-to-
person transmission of, 60
Respiratory syncytial virus, 155
formalin-inactivated vaccine
and, 70
Respiratory viruses, 66
organs targeted by, 61–62
Retrospective cohort studies, 293
Retroviruses, quality control testing
and, 201t
Reverse genetics, 165, 172–173, 179
Reverse vaccinology, 173–174, 179
defined, 121
development of Neisseria meningitidis
type B candidate vaccine
by, 174
pathway in, 122
Reye's syndrome, varicella and, 17
Rheumatoid arthritis, targeting host
proteins and, 115
Rhinoviruses, 60
Rice-based vaccines, 144
Rickettsia prowazekii, 70
Rickettsia rickettsii, 14
Rickettsias, 61, 199
Rift Valley Fever virus, 139
RIG-I defined, 76
RIG-I innate immune sensing
pathway, 67
RIG-I ligands, 105
Rig-I-like receptors, 74, 149
Rinderpest virus, 184, 324
efforts to control, 49
global control of, 50
maternal transfer of antibodies and
protection from, 49
pandemic in Africa and “stamping
out” policy, 50
“serum-simultaneous procedure”
and, 50
vaccination and, 49–51, 109
wildlife species affected by, 49
Ring immunization, 2, 156, 282
Ring vaccination, smallpox and, 48
Risk-benefit ratio, New Drug
Application and, 267
Risk communication, elements
in, 300
Risk compression, applied to vaccine
decision making, 347t
Risk perception, media, irrational
behavior, and, 300–301
RLRs. See Rig-I-like receptors
RNA microarrays, 257
RNA viruses, 133–139
alphavirus vectors, 133–135
flaviviruses, 137
lentiviruses, 137–139
measles virus, 136
Newcastle disease virus,
135–136
rabies virus, 136–137
vesicular stomatitis virus, 136
Robbins, Frederick, 10
Rockefeller Foundation, 327
Rockefeller Institute, 9
Rocky Mountain Spotted Fever, 14
Rotarix, 86, 165, 171, 281, 289
RotaShield, 44, 171
VAERS intussusception
identification among children
vaccinated with, 292
Index

RotaTeq, 86, 165, 171, 281, 289
  RCA study of intussusception
  and, 295
RotaTeq Torarix, 44
Rotavirus gastroenteritis, 31
Rotavirus tests, percentage of positive,
  by week and year, USA, 2000–2010, 31
Rotavirus vaccine, 30–31, 171, 263
generiic region and variation
in, 323
intussusception following receipt
of, 289, 292
reassortment and, 165
summary of safety trials with
  emphasis on intussusception
  following receipt of, 290
  two candidates, summary of
efficacy trials of, 290
Rotaviruses, 30, 44, 60, 88, 320
mechanisms of vaccine-induced
  protection against, 91–92
multi-segment nature of, 111
SIR model and, 316
Routes of administration, of
  commonly used vaccines, 157, 158–160
RPV. See Rinderpest virus
RSIVD. See Red sea bream iridoviral
disease
RSV. See Respiratory syncytial virus
Rubella, 15, 178, 192, 320
as eradicable disease with
  vaccination, 178t, 323
Netherlands, September
  2004–2005, 16t
population-based vaccination
  programs and, 336
value of herd immunity threshold
  for, 313t
values of \( R_0 \) for, 312t
Rubella vaccine, 3
  “Rules Governing Medical Products in
  the European Union, The,” 237
Russian Federation, diphtheria cases
  in, 1992–2006, 5, 5
Russian Revolution, typhus
during, 70
RV. See Rabies virus
RVFV. See Rift Valley Fever virus

S. salivarius, beta-D-fructosyltransferase
  Fits of, 141–142
Sabin, Albert, 11, 52
Sabin attenuated live oral polio
  vaccine, 86
Saccharomyces cerevisiae, 170, 171,
  252
SADC. See South African
  Development Community
Safety, vaccines, 218, 257, 287–303,
  331–332. See also Clinical
evaluation of vaccines
  approval process, 291
causality assessment, 296–298
Clinical Immunization Safety
  Assessment network, 295
examples of CISA
  studies, 295–296
clinical studies with human
  subjects, 289
  phase I trials, 289
  phase II trials, 289
  phase III trials, 289
communication perspective
  in, 300–301
defined, 195, 236
ENCePP and, 296
EU requirements for veterinary
  vaccines, 238
government and, 338
nonclinical, vaccines and, 36, 207
  passive and active surveillance
  systems, 291–293
  post-licensure safety and efficacy
  monitoring, 291
public health and public
  communication, 301–302
  rapid cycle analysis (RCA)
  studies, 295
vaccine approval and, 33
  clinical trials, 39
  definition of, 35
  good manufacturing practice
  and, 37
in vaccine development, initial
  exploratory discovery and
  nonclinical phase, 288–289
vaccine fears, examples
  cancer, 299
  mad cow disease, 298
  MMR vaccine and
  autism, 298–299
oral polio vaccine trials in
  Belgian Congo and
  HIV, 299–300
Vaccine Safety DataLink
  project, 293
examples of VSD studies, 294
veterinary vaccines and, 236, 242
widespread questioning of, 341
SAGE. See Strategic Advisory Group
  of Experts on Immunization
Salk, Jonas, 11, 52, 166
Salk polio vaccine, dissemination by
  philanthropic foundation, 338
Salmon, second- and third-generation
  licensed/commercialized viral
  vaccines for, 185t
Salmon lice infections, 190
Salmonella minnesota LPS, 104
Salmonella spp., 86, 143, 186
Salmonella typhi, 2, 3
Salmonella typhi Ty21a, 163
Salmonella vaccines, 139
Salmonellosis, 233
Salmonids, bacterial infections
  in, 189
Sanofi Pasteur, 196, 281, 326
Saponins, 102
SAR. See Secondary attack rate
SARS-CoV. See Severe acute
  respiratory syndrome coronavirus
Scale-up, vaccine development
  and, 244
Scarlet fever, value of herd immunity
  threshold for, 313t
School-entry immunizations,
  required, exemptions from, 352
Schools, vaccine mandates for, 340
Schwatz strain, of measles virus,
  205
Second-generation vaccines,
  defined, 183
Secondary attack rate
  calculating, 309
  defined, 308
formula for, 308
measles vaccine efficacy and, 309
  transmission probability (\( \beta \))
  and, 308–310
SEIR model, 317
  for smallpox, 316
SEIS model, 317
  for tuberculosis, 316
Semliki Forest virus, 133–134  
Sepsis, 63, 64, 65  
Serials, 238  
Serious adverse events defined, 288  
FDA definition of, 331  
Serologic correlates, defined, 203  
Seroprotection, defined, 203  
Serum immunity, 2  
Serum Institute of India, 323  
“Serum sickness,” 5  
Seven-valent pneumococcal conjugate vaccine (PCV7), 46  
Severe acute respiratory syndrome, values of \( R_0 \) for, 312t  
Severe acute respiratory syndrome coronavirus, 240  
Severe acute respiratory syndrome virus, 136  
Sexual transmission, 60  
Sexually transmitted diseases, for vaccine research and development, 321t  
SFV. See Semliki Forest virus  
Shanghai-191 measles strain, 251  
Sheep  
bacterial vaccines for, 186t  
protozoal vaccines for, 187t  
viruses of global importance in, 184t  
Shigella spp., 86, 143  
Shingles, 2, 16, 18, 153, 154  
Sickle cell disease, 283  
Signs defined, 60  
natural history and, 306  
Simian immunodeficiency virus, 137, 138, 299  
Simian parainfluenza virus 5, 136  
Simian virus 40, 11, 299  

studies of, 11–12  
Simultaneous vaccines, defined, 175  
Sindbis virus, 133  
Single-blinded studies, 264  
Single-cycle viruses, 129  
Single-round infectious particle vaccines, defined, 153  
Single-round infectious particles, 155  
SINV. See Sindbis virus  
SIR. See Susceptible infectious recovered model  
SIS model, 317  
Sister Kenny, 10  
SIV. See Simian immunodeficiency virus  
Slaughter policies, infectious animal diseases and, 240  
Smallpox, 88, 178, 214, 333, 340  
CBRN medical countermeasures against, 285  
as eradicable disease with vaccination, 323  
eradication of, 2  
mechanisms of vaccine-induced protection against, 90–91  
origins of, 46  
rash characteristic of, 46  
SEIR model for, 316  
transmission and symptoms of, 46  
use of vaccination against, 46–48, 109  
value of herd immunity threshold for, 313t  
vvalues of \( R_0 \) for, 312t  
Smallpox vaccines, 73  
biological weapon concerns, 176  
in 18th century, 1–2  
Social environmental factors, 305  
Social marketing model, 341, 343, 345  
Social media, 349  
SOPs. See Standard operating procedures  
SORD. See Surveillance and Outbreak Response Division  
South African Development Community, 268  
Span 85, 100  
Special populations. See Vaccine exceptions for special populations  
Specific pathogen-free (SPF) chicken eggs, measles virus vaccine and, 251  
Spodoptera frugiperda, recombinant influenza vaccine and, 171  
Sponsors, 261, 272  
defined, 262  
investigational new drug process and, 266, 267  
responsibilities of, 268–269  
Spring viremia of carp, 190  
Squalene, 100  
SSPE. See Subacute sclerosing panencephalitis  
Standard operating procedures, 208, 209  
Standard review, 223  
Staphylococcus, 67  
Staphylococcus aureus, protein A of, 141  
Staphylococcus carnosus, 142  
Steering Committee, ICH  
harmonization activities and, 268  
Sterility tests, 250  
Stochastic models, 314  
Strategic Advisory Group of Experts on Immunization, 329  
Streptococcus pneumoniae, subunit vaccines and, 71  
Streptococcal bacteria, spread of, 60  
Streptococcus mutans, surface protein antigen P1 of, 141  
Streptococcus pneumoniae, 21–22, 45, 84, 167, 168, 283  
Streptococcus pyogenes, 17  
M6 protein of, 141  
Streptococcus spp., 67  
Streptococcus suis, in cattle, 186  
Streptococcus vaccine, potency assays with recommended human vaccine dose, 202t  
Study records, GLP regulations and, 209–210  
Subacute sclerosing panencephalitis, 13, 54  
Subclinical infections, 60  
Subcutaneous (SC) route of administration for, 142  
hepatitis B virus and, 71  
Neisseria meningitidis and, 71  
recombinant DNA technology and, 170  
Streptococcus pneumoniae and, 71  
in veterinary medicine, 185  
Surface-exposed lipoproteins, 141  
Surrogate of protection, defined, 89  
Surveillance, disease, 337–338
Surveillance and Outbreak Response Division, 298
Susceptible infectious recovered model, 315, 315–316
basics of, 315
disease examples and use of, 316
dynamics of, 316
variations of, 317
Suspected adverse reactions, 297
SV40. See Simian virus 40
SVC. See Spring viremia of carp
Symptomatic period, 307
Symptoms
defined, 60
natural history and, 306
Synaptobrevin, 68
Synco BioPartners (Netherlands), 323
Syphilis, 2, 307
Systems biology, 117
defined, 118
high-throughput methods and, 117–120
Systems biology analysis software applications/databases, commonly used, 120
SYSVAK, 291

T cell-dependent B-cell responses, 81, 82
T cell-independent antigens, 84
T cell-independent B-cell responses, 84
T-cell independent response, 167
T-cell populations, adjuvants and, 95
T-cell receptor, defined, 78
T-cell responses, primary and secondary, to pathogens or vaccine antigens, 74
T cells, 115
adaptive immune responses in gut mucosa and, 87
antigen recognition by, 79
 correlates of protection and, 89
T lymphocyte immunity, 79–80
T lymphocytes, 73, 77, 78, 95
antigen delivery vehicles and, 97
cytotoxic, 65
differentiation process for, 79–80
Tailored health communication, 341, 343
Tangential flow filtration, 205
Tauopathies, 115

TB. See Tuberculosis
TCT. See Tracheal cytotoxin
TD-97 measles strain, 251
Tdap vaccines, 8, 156, 167
Technical Report Series, 332
Testing
for recombinant HPV VLP vaccines, 254–256
of vaccine potency and immunogenicity, 201–202
of vaccines at specific stages of product processing and release, 201
Tetanospasmin, 68
Tetanus, 2, 5, 6–7, 62, 68, 88, 320
maternal, 156
neonatal, 6, 6, 156, 323, 324
Tetanus toxin, mechanisms of vaccine-induced protection against, 90
Tetanus toxoid, 111
impact among US soldiers, 6t
Tetanus vaccines, 110–112, 111, 167
potency assays with recommended human vaccine dose, 202
TFF. See Tangential flow filtration
TGA. See Therapeutic Goods Administration
Th-17, defined, 78
Therapeutic Goods Administration (Australia), 36, 198, 265, 266, 273
Therapeutic Goods Agency (Australia), 332
Therapeutic immunization, 153
Therapeutic vaccination/vaccines, 4, 19, 114–116
Thermovax, 50
Thimerosal, 258
VSD study on neuropsychological outcomes at 7 to 10 years, 294
Third-generation vaccines defined, 183
DNA vaccines, 171–172
Third World Congress on Alternatives and Animal Use in Life Sciences, 256–257
13-valent pneumococcal conjugate vaccine, 22
13-valent vaccine, 168
Throat cancer, human papillomaviruses and, 26
Thrombocytopenic purpura, ideopathic, VAERS investigation of MMR vaccines and, 292
Thymectomy, vaccine recommendation and, 283
Thyroid disease, VSD study on hepatitis B vaccine and, 294
Tick bites, 61
Tissue injury and disease, mechanisms of, 62–63, 65
TIV. See Trivalent inactivated influenza vaccine
TLR3, 149
TLR4, 117
TLR5, 149
TLR7, 117, 149
TLR9, 149
TLR agonists, as adjuvants, 149
TLR3 ligands, 105
TLR signaling, 76
TLR-signaling pathways, immunostimulatory adjuvants and, 104
TLRs. See Toll-like receptors
Toll-interleukin (IL)-1 receptor domain, 75
Toll-like receptor agonists, immunostimulatory adjuvants and, 104
Toll-like receptor 4, 65
Toll-like receptor ligands, PLGA matrices and, 145
Toll-like receptors, 67, 117, 149
defined, 73
innate immunity and, 75–76
Tort law, evolution of, 339
Toxicology, 110
Toxicology studies of nonclinical vaccines, 207
vaccine development and, 37
Toxin-mediated diseases, 68–69
anthrax, 69
diphtheria, 68–69
tetanus, 68
Toxoid bacterium vaccine, doses and routes of administration for, 159
Toxoid vaccines, 161t, 167
defined, 153
examples of, 154
Toxoids, 67
Toxoplasma gondii, 187
TP. See Thrombocytopenic purpura
Index

Vaccine delivery systems
novel, 142–144
bacterial ghost system, 142–143
genetic vaccination, 143–144
Vaccine design principles, 193–194
Vaccine development
discovery and basic science
phase, 109–125
basic science and translational research behind, 109–110
bioinformatics and reverse vaccinology, 120–122
classical pathway in, 121
high-throughput methods and systems biology, 117–120
immunology of protection and adjuvants, 116–120
iterative cycle of vaccine development, 123
molecular biology and recombinant vaccines, 113–114
personalized vaccinology and, 123–124
therapeutic vaccines and vaccines against noninfectious agents, 114–116
vaccine delivery and, 123
key considerations for, 193t
major steps in research and development pathway, 194
time line for, 262, 325
Vaccine development pathway, 33–42, 198–199
basic research and development, 36–37
biologics license application, 40–42
alternative pathways to licensure, 41–42
meetings with regulatory agencies, 40
post-licensure activities, 41
clinical trials, 39–40
major phases of, 38
Food and Drug Administration guidance documents, 40–41
investigational new drug application, 38
manufacturing and process development, 37–38
market need and, 35
primary considerations in approval, 33–34
regulation and approval, 35–36
terms and definitions, 35
typical phases of development and approval, 34
Vaccine efficacy defined, 195
secondary attack rates and, 309
Vaccine European New Integrated Collaboration Effort project, 292
Vaccine exceptions for special populations, 277, 281–285
aging adult population, 281–282
altered immunocompetence, 282–283, 286
asplenia, 283
children, 277, 281, 286
college students, 285
health care workers, 285
human immunodeficiency virus, 283–284
military members, 283, 286
newborns, 282
occupational risks, 285
pregnant women, 282
thymectomy, 283
travelers, 284–285, 286
Vaccine exemptions, defined, 277
Vaccine failure, 336
Vaccine hesitancy, growth of, 338
Vaccine-hesitant parents, 351–352
Vaccine-induced protection exotoxin-producing bacteria, 90
mechanisms of, 90–92
rotavirus, 91–92
varicella zoster virus, 91
typhoid fever, 90
yellow fever, 90
Vaccine Information Statements, 291
Vaccine Injury Compensation Program, 339
Vaccine manufacturing processes, examples of, 204t
Vaccine-preventable illnesses declining incidence of, 192
in U.S., before and since routine childhood vaccination, 3t
Vaccine regulatory control, history behind, 5
Vaccine Safety DataLink (VSD) project, 293–294
Vaccine Safety Section, 298
Vaccine shortages, 339
Vaccine-specific antibody, persistent production of, 82–83
Vaccine vectors good, characteristics of, 129–130
potential difficulties with, 129
Vaccine Vigilance Working Group, 298
Vaccine Working Group, 256
Vaccines. See also Adjuvants; Immunization; Licensed vaccines for humans; Safety, vaccines; Vaccination advantages of using virus vectors as, 128–129
anthrax, 139, 177
antiallergy, 161, 179
bacterial subunit, 166
for biodefense and biothreat agents, 35, 176–177
“blockbuster” status and, 33
both live and attenuated, 175–176
brucellosis, 177
cancer, 179
characteristics of, 324t
childhood, impact in USA, 20th century, 178t
chimeric, 185
cholera, 166
combination, 174, 175t, 281, 297, 324t
conjugate, 168–169, 179
correlates of protection and, 88–89
cost increases for, 339
definitions for, 153
delivery of, 123
derivation of word, 4
diphtheria, 4–6, 167
disease control with, 20th century, 2–4
DNA, 116, 143, 155, 171–172, 185
extensive national infrastructures around, 43
first-generation, 183
foot-and-mouth disease, 55
global sales of, 326
Index

Vaccines (cont’d)
GMO, 223, 224
goal of, 88, 96
good candidate adjuvants and, 95
Haemophilus influenzae, Type b
(Hib), 20–21
hepatitis B, 252
for hepatitis viruses, 23–26
historic dates and events related to licensing, 245–247
human papillomavirus, 26, 88, 113, 146, 233, 244, 262, 263, 274, 338
ideal, characteristics of, 161
implementation components, 329
importance of in public health, 244
inactivated, 165–166
for infectious diseases, 67–68
influenza, 28–30, 251, 349
killed or inactivated, 2
lack of generic, 178–179
lentivirus-based, 138, 139
licensure of, 35–36, 43
mandates, 275, 340
measles, 12–15, 54, 136, 157, 251–252, 337
meningococcal, 168
MMR, 252, 275, 276, 281, 282, 298–299, 345–346, 349
mucosal-based, 88, 161
multiple, given on same day, examples of, 175
multiple uses and, 166
mumps, 15–16
Neisseria meningitidis, 22–23
for noninfectious diseases, 114–116, 177–178
personalized, 179
pertussis, 7–8
plague, 177
poliomyelitis, 10–12, 52–53, 53, 166
polysaccharide, 167–168, 179
for polysaccharide encapsulated bacteria, 19–20
post-licensure period, 41, 44, 273–274
poverty, 35
prequalified, 330
product timeline for, 193, 210
Q fever, 177
rabies, 166, 244
recombinant, 110
DNA-derived, 170–171
molecular biology and, 113–114
subunit, 179
recommendations, 274–275
regulation and approval of, 35–36
rice-based, 144
rinderpest, 50
rotavirus, 30–31, 44, 171, 263
routes of administration for, 157, 158–160
rubella, 3, 15
safety concerns and, 96–97
Salmonella, 139
second-generation, 183
shortages of, 339
smallpox, 1–2, 47, 73, 176
Streptococcus pneumoniae, 21–22
subunit, 71, 110, 113, 117, 142, 185
tetanus, 6–7, 110–112, 111, 167
in the 20th and 21st centuries, 178
therapeutic, 114–116
third-generation, 183
toxoid, 167
travel-related, 177, 284–285, 284t, 325
trial and error and development of, 4
tuberculosis, 142 tularemia, 177
types of, 161
typhoid, 168
varicella zoster virus, 16–19, 153–154
vaccination, 181–191
adjuvants for, 106–107, 107t
viral subunit, 169
yellow fever, 8–10, 325, 327
Vaccines and Related Biological Products Advisory Committee, 40, 265, 266
Vaccines for Children Program, 43, 340
Vaccinia virus, 2, 130
Vaccinology complex, interdisciplinary nature of, 124
high-throughput profiling and, 119–120
political, ethical, social, and psychological aspects of, 335–333
politics in, 336–340
commercial development, 339–340
disease surveillance, 337–338
equitable access, 340
injury compensation, 339
official recommendations, 340
philosophical basis for, 336–337
product regulation, 338
public communication, 338–339
vaccine mandates, 340
reverse, 173–174, 179
Vaccinology, origins of, 47
VAERS. See Vaccine Adverse Event Reporting System
VAPP. See Vaccine-associated paralytic poliomyelitis
VAR. See Vaccine Administration Record
Variant Creutzfeld-Jacob disease, 298
Varicella vaccine, 17, 153–154
CISA study on role of genetics in immune response to, 296
side effects with, 18
Varicella virus, 2, 16–18, 88, 153, 320, 339
Group A streptococcal fasciitis in normal child with, 17
mortality rates with, 17
Varicella zoster (shingles) vaccine, 282
Varicella zoster virus (chickenpox/zoster), 2, 16–20
age-related cellular immune response to, 19
early vesicle formation, 16
mechanisms of vaccine-induced protection against, 91
Variola (smallpox), mechanisms of vaccine-induced protection against, 90–91. See also Smallpox
Variolation, 1, 46–47, 337
Varivax, 91
VE. See Vaccine efficacy
Vector-borne transmission, of infectious agents, 306
Vector-borne viral diseases, for vaccine research and development, 322
VECTOR Institute, 48
Vectors, 304, 305
Venezuelan equine encephalitis virus (VEEV), 133
VENICE II project. See Vaccine European New Integrated Collaboration Effort project
Vesicular stomatitis virus, 113, 136
Veterinary Biological Product License, 234, 236
Veterinary Biologics Establishment License, 234
Veterinary vaccination, “marker vaccines” and, 114
Veterinary vaccines, 181–191
adjuvants for, 106–107, 107t
animal testing during development of, 239
for aquaculture, status of, 188–190
bacteria, 186–187
cost-effectiveness of, factors affecting, 182, 183
development time line for, 325
fungi, 188
future challenges with, 190, 242
global market for, 232–233, 326
human vs. veterinary vaccine development, 233
for infectious and noninfectious diseases, status of, 183
international arena for, 330–331
international regulation of, 333
parasites, 187–188
in public health, impact of, 239–240
rationally designed virus vaccines, 184–185
regulations overview of, 233
USA, European Union, and Australia, 234, 236–239
regulations and impact on emerging infectious diseases, 232–242
research and development phases for, overview, 235t
selecting vaccine targets, factors in, 182
selection for companion and food-producing animals, 181–183
serology and, 114
viruses, 183–184
VHS. See Viral hemorrhagic septicemia
Vi capsular polysaccharide vaccine, 168
Vibrio cholerae, 60, 86, 143, 166
Vibrio spp., bacterial infections of fish and, 189
Vibriosis, 233
VICP. See Vaccine Injury Compensation Program
VigiSearch database, 291
Viral diseases
global vaccine preventable, 320
for vaccine research and development, 322t
Viral genome, reassorting, vaccine production and, 111–112
Viral hemorrhagic septicemia, 190
Viral pathogens, portals of entry for, 62t
Viral plaque reduction, 124
Viral vaccines
second- and third-generation licensed/commercialized, by target animal, 185t
subunit, 169
Viral vectors, 257
Viremia/bacteremia, 88
Virology, 110, 125
Virosomes, 100, 123, 125
Virulence, 305
Virus harvest, quality control testing and, 201, 201t
Virus-like particles, 113, 123, 134, 139, 146, 150, 155, 169, 244
Virus reassortment, 112, 163, 164, 165
Virus-Serum-Toxin Act (1913), 234
Virus vectors, as vaccine platforms, 128–130
Viruses
abbreviations for, 130
DNA, 130–134
of global importance in veterinary medicine, 183, 184t
multi-segment, 111
reassortant, 111
RNA, 133–139
single-cycle, 129
veterinary vaccines against, 183–185
VIS. See Vaccine Information Statements
VLPs. See Virus-like particles
Volunteers, 264
clinical trials, 261
defined, 262
von Heine, Jacob, 10
VRBPAC. See Vaccines and Related Biological Products Advisory Committee
VSD. See Vaccine Safety DataLink
V770-NP1-R, 177
VSV. See Vesicular stomatitis virus
Vulnerable populations, institutional review board and, 271
VWG. See Vaccine Working Group
VZIG. See Anti-varicella immunoglobulin
VZV. See Varicella zoster virus
Wakefield, Andrew, 345, 346
Wakefield hypothesis, MMR vaccine, autism, and, 343
Wales, pertussis attack rate in, 8
Washington, George, 337
Waterborne transmission, of infectious agents, 306
Weekly Epidemiological Record, 329
Wellcome Trust, 327
Weller, Tom, 10
West Nile virus, 132, 137
chimeric vaccines for, 185
“iceberg” of infection, 111, 111
transmission of, 306
Western blot assay, 250
Western blotting method, 119
Western equine encephalitis virus, 61
“Wet lab” methods, 121
WHA. See World Health Assembly
Whirling disease, 190
White spot disease, 190
WHO. See World Health Organization
Whole-cell inactivated bacterium, manufacturing process and vaccine examples, 248t
Whole genome sequencing, 121
Whooping cough, 2, 62–63, 166
WI-38 human diploid lung fibroblasts, 157
Wickman, Ivar, 10
“Wild-type” infectious particle, 134
Index

Wild-type viruses
live attenuated virus vaccines and, 183
poliovirus and Cutter Incident, 166
poliovirus serotype 2 eradication, 176
Wildlife
emerging infectious diseases and, 241
second- and third-generation licensed/commercialized viral vaccines for, 185
Wildlife habitats, infectious diseases and encroachment on, 240
Wistar Institute, 299
WNV. See West Nile virus
Working cell bank
defined, 249
recombinant HPV VLP vaccines and control of, 255
Working seed lot, 244, 247, 249
World Bank, 327
World Health Assembly, 48, 51
World Health Organization, 2, 34, 44, 54, 90, 186, 205, 206, 250, 268, 327, 340
age group immunization recommendations, 325
Collaborative Centres for Reference and Research on Influenza, 258
estimate on vaccine-preventable deaths of children, 320
Expanded Programme on Immunization, 297
Expert Committee on Biological Standardization, 36, 332
Global Advisory Committee on Vaccine Safety, 331
Global Training Network on Vaccine Quality, 332
goal of, 334
"Immunization, Vaccines and Biologicals" program, 329
immunization chart for routine immunization, 276–277
on impact of infectious diseases, 239
international packaging and shipping guidelines, 250
longevity-related statistics, 178
manufacturing guidance documents, 256
neonatal tetanus program, 156
prequalified vaccines service, 330
Strategic Advisory Group of Experts on Immunization, 55, 329
Uppsala Monitoring Centre, 291
vaccine development and role of, 320
vaccine prequalification process of, 257
vaccine recommendations of, 275
World Organization for Animal Health, 51, 240, 330, 331
World Trade Organization, 332
World War I
tetanus toxoid among US soldiers during, 6t
typhus during, 70
World War II
tetanus toxoid among US soldiers during, 6t
typhus vaccine used during, 70
Worldwide regulatory authorities, 227–229
WSB. See Working cell bank
WSL. See Working seed lot
YEL-AVD. See Yellow fever associated viscerotopic disease
Yellow fever, 8–10, 71, 88, 177, 214, 320
mechanisms of vaccine-induced protection against, 90
Paraguay outbreak (2007–2008), 257
symptoms of, 9
transmission of, 8–9
values of $R_0$ for, 312
Yellow fever associated viscerotopic disease, 10
Yellow Fever Commission, 8
Yellow fever vaccine, 325, 327
potency assays with recommended human vaccine dose, 202
17D vaccine, development and production of, 205–206, 206
side effects of, 9–10
for travelers, 284, 284
Yellow fever virus, 137, 173
Yellow fever virus disease, golden hamster as model for, 207
Yersinia enterocolitica, 143
Yersinia pestis, 176, 177
Yersinia pestis Yop effectors, 67
Yersinia pseudotuberculosis, 140, 141
Yersinia spp., 143, 189
YFV. See Yellow fever virus
Zoonoses, defined, 239
Zoonotic bacteria, vaccine development against, 186
Zoonotic diseases vaccination programs against, 240
for vaccine research and development, 322
Zoonotic pathogens, emerging infectious diseases and, 240, 240, 241
Zostavax vaccine, 91
Zoster (shingles), 18, 153